Patch Pump

Abstract

The injection device may include a housing, a container disposed within the housing for containing a fluid and having a first end and a second end, a conduit movable relative to the container, the conduit configured to be out of fluid communication with the fluid contained by the container when in a first position and in fluid communication with the fluid contained by the container when in a second position to deliver the fluid from the container to a patient, and a lock removable from the housing, the lock having a first portion and a second portion.

Description

[Technical field]

[0001] SUMMARY The present disclosure is directed to auto-injectors and related methods of use. [Background technology]

[0002] In various commercially available autoinjectors, activation by the user deploys a needle that delivers fluid into the user. After fluid delivery is complete, the needle may be retracted for user comfort, needle safety, and positive product perception. However, many autoinjectors may be unintentionally activated if dropped or subjected to vibration. Additionally, many autoinjectors may lack the proper control logic to stop the injection at the appropriate time. Summary of the Invention

[0003] In one aspect, the disclosure is directed to an injection device. The injection device may include a housing, a container disposed within the housing, containing a fluid and having a first end and a second end, a conduit movable relative to the container, the conduit configured to be out of fluid communication with the fluid contained by the container when in a first position and in fluid communication with the fluid contained by the container when in a second position to deliver the fluid from the container to a patient, and a lock removable from the housing, the lock having a first portion and a second portion. In a first configuration in which the lock is coupled to the housing, the first portion of the lock may be disposed outside the housing, and the second portion of the lock may be disposed within the housing between the container and the conduit, and in the first configuration, the conduit may be prevented from moving into fluid communication with the fluid contained by the container by the second portion of the lock, and in a second configuration in which the lock is removed from the injection device, the conduit may be capable of moving into fluid communication with the fluid contained by the container.

[0004] In another aspect, an injection device may include a housing, a plunger coupled to the housing and movable relative to the housing, and one or more electronic components used during an injection performed by the injection device, the one or more electronic components formed in an electrical circuit, in a first configuration, a first portion of the plunger may be disposed within the housing, the electrical circuit may be open, and the one or more electronic components may be in a low power sleep mode, and in a second configuration, the plunger may move outwardly relative to the housing, the first portion of the plunger may extend outside the housing, and in the second configuration, the electrical circuit may be closed, and the one or more electronic components may be transitioned from the low power sleep mode to an active mode.

[0005] In another aspect, an injection device may include a housing including a curved underside, the curved underside being concave when viewed from a point exterior to the housing that is closer to the underside of the housing than to an upper surface of the housing; a circuit board disposed adjacent the underside of the housing, the circuit board including a skin sensor configured to detect the presence of skin in contact with the underside of the housing; and a controller coupled to the circuit board, the controller configured to initiate an injection with the injection device only after the skin sensor detects the presence of skin in contact with the underside of the housing.

[0006] In another aspect, the present disclosure is directed to a method of manufacturing an injection device, which may include depositing a first material having a first opacity onto a mold, depositing a second material having a second opacity higher than the first opacity around the mold and the first material, and disposing a container containing a medicament within the injection device and adjacent to a first portion of the injection device formed by the first material.

[0007] In another aspect, an injection device may include a container disposed within the housing and having a first end and a second end, a piston configured to move from the first end of the container toward the second end of the container to dispense a medicament from the container, a drive member configured to drive the piston through the container, an emitter configured to emit a light beam toward the container, a detector disposed opposite the container and configured to receive the light beam emitted from the emitter, and a controller coupled to the drive member, the emitter, and the detector. The controller may be configured to receive a first signal corresponding to an ambient light level surrounding the injection device from the detector while the emitter is off and a second signal from the detector while the emitter is on, calculate a difference between light values ​​represented by the first signal and the second signal, and stop operation of the drive member when the difference is less than a threshold value.

[0008] In another aspect, an injection device may include a container disposed within the housing and having a first end and a second end, a piston configured to move from the first end of the container toward the second end of the container to dispense a medicament from the container, a drive member configured to drive the piston through the container, an emitter configured to emit a light beam toward the container, the emitter disposed on an opposite side of the container and a detector configured to receive the light beam emitted from the emitter, and a controller coupled to the drive member, the emitter, and the detector. The controller may be configured to activate the drive member and the emitter, receive a first signal from the detector representative of an amount of light received by the detector while the emitter is on, enable continued operation of the drive member for a first period of time immediately following activation of the drive member, and cease operation of the drive member upon determining that (1) the amount of light received by the detector is less than a first threshold amount of light, and (2) the amount of light received by the detector subsequently rises to or above the first threshold amount of light, and

[0009] In another aspect, an injection device may include a container disposed within the housing and having a first end and a second end, a piston configured to move from the first end of the container toward the second end of the container to dispense a medicament from the container, a drive member configured to drive the piston through the container, and a controller coupled to the drive member. The controller may be configured to maintain a speed of the drive member until a current in the drive member exceeds a first threshold, and to reduce a voltage of the drive member after the current in the drive member exceeds the first threshold to maintain the current in the drive member below a second threshold that is equal to or greater than the first threshold.

[0010] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate various examples and, together with the description, serve to explain the principles of the disclosed examples and embodiments. Aspects of the present disclosure may be implemented in conjunction with the embodiments illustrated in the accompanying drawings, which depict different aspects of the disclosure, and where appropriate, reference numerals designating like structures, components, materials, and / or elements in different figures are similarly labeled. It is understood that various combinations of structures, components, and / or elements other than those specifically shown are contemplated and are within the scope of the present disclosure.

[0011] Moreover, many embodiments are described and illustrated herein. The present disclosure is not limited to any single aspect or embodiment thereof, nor to any combination and / or permutation of such aspects and / or embodiments. Moreover, each of the aspects of the present disclosure and / or its embodiments may be used alone or in combination with one or more of the other aspects and / or embodiments of the present disclosure. For the sake of brevity, certain permutations and combinations are not separately described and / or illustrated herein. In particular, an embodiment or implementation described herein as "exemplary" should not be construed as being preferred or advantageous over other embodiments or implementations, for example, but rather is intended to reflect or indicate that the embodiment(s) are "example" embodiment(s). [Brief description of the drawings]

[0012] [Figure 1] FIG. 1 is a perspective view of an autoinjector according to an example of the present disclosure. [Figure 1A] FIG. 1 is a perspective view of a portion of a housing of an autoinjector according to the present disclosure. [Figure 1B] FIG. 1 is a perspective view of a portion of a housing of an autoinjector according to the present disclosure. [Diagram 2] FIG. 2 is a bottom view of an autoinjector according to the present disclosure. [Diagram 3] FIG. 1 is a side view of an autoinjector showing an activation switch extending away from the tissue-facing surface in accordance with the present disclosure. [Figure 3A] 1 is a cross-sectional view of an autoinjector showing an activation switch extending away from the tissue-facing surface in accordance with the present disclosure; [Figure 3B] FIG. 1 is a cross-sectional view of an autoinjector showing an activation switch in a partially depressed position in accordance with the present disclosure. [Figure 3C] FIG. 1 is a cross-sectional view of an autoinjector showing an activation switch in a fully depressed position in accordance with the present disclosure. [Figure 4] FIG. 1 is an exploded view of an autoinjector according to the present disclosure. [Figure 4A] FIG. 1 is a schematic diagram of a control system for an autoinjector according to the present disclosure. [Figure 4B] FIG. 1 is an exploded view of an autoinjector according to the present disclosure. [Figure 4C] FIG. 2 is a perspective view of a portion of a housing and an electronics board according to an aspect of the present disclosure. [Diagram 5] FIG. 13 is an exploded view of a needle mechanism according to the present disclosure. [Figure 5A] FIG. 1 is a perspective view of a fluid conduit according to the present disclosure. [Figure 5B] 1 is a cross-sectional view of a needle of a fluid conduit according to the present disclosure. [Figure 6] FIG. 6 is a perspective view of the needle mechanism of FIG. 5 in a first position in accordance with the present disclosure. [Figure 7] FIG. 6 is a side view of the needle mechanism of FIG. [Figure 8]FIG. 6 is a side view of the needle mechanism of FIG. [Figure 9] FIG. 6 is a side view of the needle mechanism of FIG. [Figure 10] FIG. 6 is a side view of the needle mechanism of FIG. [Figure 11] FIG. 6 is a side view of the needle mechanism of FIG. [Figure 12] 1 is a side cross-sectional view of a portion of an autoinjector according to the present disclosure; [Figure 13] FIG. 2 is a side cross-sectional view of a drilling mechanism according to the present disclosure. [Figure 13B] 1 is a side cross-sectional view of an autoinjector according to the present disclosure. [Figure 14] FIG. 2 is a side cross-sectional view of a drilling mechanism according to the present disclosure. [Figure 15] FIG. 1 is a side view of a needle insertion switch according to the present disclosure. [Figure 16A] FIG. 1 is a perspective view of a lock for an autoinjector according to an aspect of the present disclosure. [Figure 16B] FIG. 1 is a bottom view of an autoinjector and lock according to the present disclosure. [Figure 16C] 1 is a cross-sectional view of an autoinjector and lock according to the present disclosure. [Figure 16D] 1 is a cross-sectional view of an autoinjector and lock according to the present disclosure. [Figure 16E] FIG. 1 is a perspective view of a lock for an autoinjector according to an aspect of the present disclosure. [Figure 16F] FIG. 1 is a side view of a lock for an autoinjector according to an aspect of the present disclosure. [Figure 17] FIG. 13 is a bottom view of an electronics board for an autoinjector according to the present disclosure. [Figure 17A] FIG. 1 is a perspective view of an electronics board for an autoinjector according to the present disclosure. [Figure 18] 1 shows a flowchart of an exemplary method according to the present disclosure. [Figure 19] 1 shows a flowchart of an exemplary method according to the present disclosure. [Figure 20] 1 shows a flowchart of an exemplary method according to the present disclosure. [Figure 20A] 1 shows a graph of the electrical control of an autoinjector according to the present disclosure. [Figure 20B] 1 shows a graph of the electrical control of an autoinjector according to the present disclosure. [Figure 21] 1 shows a flowchart of an exemplary method according to the present disclosure. [Figure 22] 1 shows a flowchart of an exemplary method according to the present disclosure. [Diagram 23] 1 shows a flowchart of an exemplary method according to the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] Again, many embodiments are described and illustrated herein. The present disclosure is not limited to any single aspect or embodiment thereof, nor to any combination and / or permutation of such aspects and / or embodiments. Each of the aspects and / or embodiments of the present disclosure may be used alone or in combination with one or more of the other aspects and / or embodiments of the present disclosure. For the sake of brevity, many of these combinations and permutations are not described separately herein.

[0014] In particular, for simplicity and clarity of description, certain aspects of the drawings show schematic structures and / or methods of construction of various embodiments. Descriptions and details of well-known features and techniques may be omitted to avoid unnecessarily obscuring other features. Elements in the drawings are not necessarily drawn to scale, and dimensions of some features may be exaggerated relative to other elements to enhance understanding of the illustrative embodiments. For example, those skilled in the art will appreciate that cross-sectional views are not drawn to scale and should not be considered as representing proportional relationships between different components. Cross-sectional views are provided to facilitate explanation of various components of the illustrated assemblies and to show their relative positions to one another.

[0015] Reference will now be made in detail to examples of the present disclosure, which are illustrated in the accompanying drawings. Wherever possible, the same reference numerals have been used throughout the drawings to denote the same or similar parts. In the following description, relative terms such as "about," "substantially," and "approximately" are used to indicate a possible variation of ±10% of the numerical values ​​stated.

[0016] As discussed above, existing autoinjectors may be unintentionally activated when dropped or subjected to vibration. In addition, existing autoinjectors may lack appropriate control logic to stop injection at the appropriate time. These shortcomings may cause premature administration of medication, increase the complexity of self-administration of medication, induce user error, or cause user discomfort. Accordingly, the present disclosure is directed to various embodiments of an injection device (e.g., an autoinjector) for self-administration of medication or other therapeutic agents by a user. Specifically, according to some embodiments, the likelihood of unintentional activation of the autoinjector may be reduced, and the autoinjector may further incorporate control logic that improves the operation and user experience of the autoinjector.

[0017] Further details of the autoinjector according to the present disclosure can be found in International Application No. PCT / US2018 / 031077, filed November 8, 2018, published as WO 2018 / 204779, which is incorporated herein by reference in its entirety. Further details of the vial piercing system according to the present disclosure can be found in U.S. Patent No. 10,182,969, filed March 10, 2016, which is incorporated herein by reference in its entirety.

[0018] Overall System Examples of such autoinjectors 2 are shown in Figures 1, 2, and 3. As shown in Figure 1, the autoinjector 2 may include a housing 3 having a tissue-engaging surface (e.g., an underside) 4 through which the needle may be deployed and retracted. As shown in Figures 1 and 1A, the housing 3 may include a transparent window 50. The transparent window 50 may allow an observer to visualize one or more displays or to visualize the interior of the autoinjector 2 and components within the autoinjector 2, such as the primary container and / or the drug product stored within the primary container.

[0019] In some embodiments, as shown in FIG. 1, the autoinjector 2 may include a plurality of openings 51 configured to allow for the movement of sound generated within the housing 3 (e.g., by a speaker). The autoinjector 2 may have any suitable dimensions that allow for portability and self-application by a user. In one example, the autoinjector 2 may have a length of about 2.98 inches (7.57 centimeters), a width of about 2.07 inches (5.26 centimeters), and a height of about 1.07 inches (2.72 centimeters). However, other suitable values ​​may also be utilized, including, for example, a length of about 0.5 inches (1.27 centimeters) to about 5.0 inches (12.7 centimeters), a width of about 0.5 inches (1.27 centimeters) to about 3.0 inches (7.6 centimeters), and a height of 0.5 inches (1.27 centimeters) to about 2.0 inches (5.1 centimeters).

[0020] The autoinjector 2 may be oriented about a longitudinal axis 40 (e.g., X-axis), a lateral axis 42 (e.g., Y-axis) that is substantially perpendicular to the longitudinal axis 40, and a vertical axis 44 (e.g., Z-axis) that is substantially perpendicular to both the longitudinal axis 40 and the lateral axis 42.

[0021] As shown in FIG. 1, an adhesive patch 12 may be coupled to the tissue-engaging surface 4 to help secure the autoinjector 2 to the user's body (e.g., skin). The adhesive patch 12 may be formed from a fabric or other suitable material and may include an adhesive. The adhesive may be, for example, a water-based or solvent-based adhesive, or may be a hot melt adhesive. Suitable adhesives also include acrylic, dextrin, and urethane-based adhesives, as well as natural and synthetic elastomers. In some examples, the adhesive provided on the patch 12 may be activated upon contact with the user's skin. In yet another example, the patch 12 may include a non-woven polyester substrate and an acrylic or silicone adhesive. The patch 12 may be joined to the housing 3, for example, by a double-sided adhesive or by other mechanisms such as ultrasonic welding. The patch 12 may have a length dimension that is greater than the width of the autoinjector 2.

[0022] As shown in FIG. 2 , the autoinjector 2 may include an opening 6 through which the needle may be deployed and retracted. An activation switch 1409 may be disposed on the tissue engaging surface 4 and configured to activate the autoinjector 2 or otherwise place the autoinjector 2 in a “ready” mode. A touch sensor 1410 may also be disposed on the tissue engaging surface 4 and configured to assist a controller of the autoinjector 2 in determining whether the autoinjector 2 is placed on the skin of a user (indicating whether the autoinjector should fire or otherwise deploy a needle) or whether the activation switch 1409 has been improperly activated (indicating that operation of the autoinjector 2 should be stopped). A connection port 13 may be disposed on the tissue engaging surface 4 to allow programming of the autoinjector 2.

[0023] The autoinjector 2 may be configured to operate in three or more phases of operation, including, for example, an injection sequence activation phase, an injection phase, and a storage phase, each of which are described in further detail herein. The injection sequence activation phase, injection phase, and storage phase may be collectively referred to herein as the "injection sequence."

[0024] 3A, 3B, and 3C, which show a cross section of the autoinjector 2, the activation switch 1409 can be a mechanical plunger-type switch. For example, the activation switch 1409 can include a plunger 1450 having a plunger contact surface 1452. The plunger contact surface 1452 can be generally circular in shape (or have another suitable shape) and can be large enough to be comfortably depressed by soft skin. In some embodiments, the plunger contact surface 1452 can have a diameter or width ranging from about 2 mm to about 10 mm, a diameter ranging from about 4 mm to about 8 mm, or a diameter of about 6 mm. The activation switch 1409 can further include a shaft 1442, a biasing member 1444, a biasing collar 1446, and a plunger flange 1454. The biasing member 1444 can be, for example, a spring and can surround the shaft 1442. The biasing member 1444 may be secured at one end or otherwise prevented from moving by a biasing collar 1446. The plunger flange 1454 may be configured to contact or otherwise depress the plunger switch 1448. For clarity, the term activation switch and / or reference to activation switch 1409 as used herein should be understood to encompass any or all components of the activation switch 1409, including the shaft 1442, the biasing member 1444, the biasing collar 1446, the plunger switch 1448, the plunger 1450, the plunger contact surface 1452, and the plunger flange 1454.

[0025] In the free state, i.e., when the plunger 1450 is not being pressed against the user's skin or otherwise depressed, the plunger 1450 may extend outwardly from the tissue engaging surface 4, as shown in FIG. 3A. In the free state, the plunger contact surface 1452 may be a distance from the tissue engaging surface 4 ranging from about 1 mm to about 16 mm, from about 5 mm to about 12 mm, or a distance of about 8.5 mm. In the free state, the biasing member 1444 may bias the plunger 1450 to extend outwardly from the tissue engaging surface by pressing against the biasing collar 1446. In the free state, the plunger flange 1454 may contact or otherwise depress the plunger switch 1448. When the plunger flange 1454 is in contact with or otherwise depresses the plunger switch 1448, the electrical circuit associated with the plunger switch 310 may be complete or closed.

[0026] When the plunger 1450 is pressed against the skin of a user or otherwise depressed, the plunger 1450 may initially move to a partially depressed state, as shown in FIG. 3B. In the partially depressed state, the biasing member 1444 may be compressed against the biasing collar 1446. The plunger flange 1454 may further be out of contact with or otherwise not depressing the plunger switch 1448. When the plunger flange 1454 is spaced from, not in contact with, or otherwise not depressing the plunger switch 1448, an electrical circuit associated with the plunger switch 1448 may be in a broken or open state. This configuration allows the autoinjector 2 to be maintained in a low power state while the plunger 1450 is depressed, such as when the autoinjector 2 is packaged.

[0027] As shown in Figure 3B, the plunger 1450 may not necessarily move to the fully depressed state (shown in Figure 3C) before the plunger flange 1454 is out of contact with the plunger switch 1448. However, as shown in Figure 3C, in the fully depressed state, the plunger 1450 may be depressed inward such that the plunger contact surface 1452 is flush or nearly flush with the tissue engaging surface 4.

[0028] The plunger flange 1454 may be out of contact with the plunger switch 1448, for example, after the plunger 1450 has moved less than 5 mm, after the plunger 1450 has moved less than 3 mm, after the plunger 1450 has moved less than 1 mm, or after the plunger 1450 has moved about 0.75 mm (all when the maximum depression distance is, for example, 8.5 mm). In other words, the plunger 1450 may transition from a free state in which the plunger flange 1454 is in contact with the plunger switch 1448 to a partially depressed state in which the plunger flange 1454 is out of contact with the plunger switch 1448 after the plunger 1450 has moved only a portion of the maximum depression distance of the plunger 1450 relative to the housing 3 of the autoinjector 2. For example, the plunger 1450 may transition to a depressed state after moving about 5%, about 10%, or about 20% of the maximum depression distance. Thus, the autoinjector 2 and plunger switch 1448 may be sufficiently responsive when the plunger 1450 is pressed against the skin of a user. For example, the autoinjector 2 and plunger switch 1448 may be sufficiently responsive when pressed against users having different skin hardnesses or different body fat content. Although examples of travel distances for the plunger 1450 are provided herein, it should be understood that the disclosure is not limited to the particular examples and any suitable travel distance may be used.

[0029] The biasing member 1444 may be sufficiently rigid in the free state to maintain the plunger flange 1454 in contact with or otherwise continuously depress the plunger switch 1448. The biasing member 1444 may also be rigid enough that the plunger 1450 may be comfortably depressed when pressed against a user's skin. The biasing member 1444 may be biased to maintain the plunger 1450 in the free state.

[0030] 3A-3C as a mechanical plunger type switch, it should be understood that the activation switch 1409 may be any other suitable type of switch, such as a rocker switch, a throw switch, a toggle switch, a temperature switch, etc. Additionally, although the electrical circuit associated with the plunger switch 1448 is described herein as being closed when the plunger 1450 is in a free state and open when the plunger 1450 is in a depressed state, it should be understood that the opposite configuration may be used. For example, the electrical circuit associated with the plunger switch 1448 may be open when the plunger 1450 is in a free state and closed when the plunger 1450 is in a depressed state.

[0031] The method of controlling the autoinjector 2 according to the position of the activation switch 1409 is described in further detail below with reference to FIG. 4B, in some embodiments, the autoinjector 2 may include multiple LEDs 52. The LEDs 52 may be arranged in a ring configuration or any other suitable configuration. As described in more detail below, the light from one or more LEDs 52 may indicate various operational states of the autoinjector 2.

[0032] Autoinjector housing 1A and 1B, the housing 3 of the autoinjector 2 may include an upper portion 30. The upper portion 30 may form a portion of the housing 3 opposite the tissue engaging surface 4. The upper portion 30 may include a transparent window 50 through which a user can observe the contents of the autoinjector 2, including the vial and / or medication contained therein. The transparent window 50 may be located on a side of the upper portion 30 and may be formed to fit the rounded or curved contour of the upper portion 30, as shown in FIG. 1. The transparent window 50 may be generally rectangular in shape with rounded corners.

[0033] The upper portion 30 may also include a plurality of transparent windows 54. The plurality of transparent windows 54 may be formed on an upper surface of the upper portion 30 and may be arranged in any suitable configuration, such as, for example, a circular, elliptical, rectangular, or linear configuration. The transparent windows 54 may be, for example, circumferentially spaced apart from one another. The transparent windows 54 may allow light from one or more LEDs disposed within the housing 3 to be visible to a user. The light from the one or more LEDs may indicate various operational states of the autoinjector 2, as described herein.

[0034] The transparent window 50 and the transparent window 54 may be integrally formed as part of the upper portion 30. As shown in FIG. 1B, the upper portion 30 may include a transparent portion 500 formed from a transparent material. The transparent portion 500 may be continuous, such that the transparent window 50 and the transparent window 54 are formed from one piece of transparent material. Additionally, the transparent portion 500 may be integrated into the upper portion 30, such that the upper portion 30, including the transparent window 50 and the transparent window 54, is manufactured as a single piece.

[0035] To form the upper portion 30 as a single piece, the upper portion 30 may be manufactured using, for example, a double shot molding process. FIG. 19 shows an exemplary method 1900 of molding the upper portion 30 using double shot molding or insert molding. In step 1910, a first material may be deposited in a first mold having a first core and a first mold cavity. The first material may have low opacity, for example, a transparent material for the transparent window 50 and the transparent window 54. The first material may be, for example, a clear acrylic, a clarified acrylonitrile butadiene styrene (ABS), a polycarbonate, a polyvinyl chloride (PVC), or a polyethylene terephthalate glycol (PETG). The first mold may be configured to form, for example, the transparent portion 500.

[0036] In step 1920, the first core and the material in the first mold cavity may be moved into a second mold cavity to form a second mold. During the move, the first core may hold the first material. The second mold may be configured to form, for example, the upper portion 30. In step 1930, a second material may be deposited into the second mold cavity containing the first material. The second material may be deposited around the first material and the first core in the open space of the second mold cavity to form the upper portion 30. The second material may be a highly opaque material, such as a white plastic. The second material may be, for example, ABS, polycarbonate, an ABS-polycarbonate blend, PVC, or PETG.

[0037] Thus, the generally opaque upper portion 30, including the transparent window 50 and the transparent window 54, may be formed from two different materials to form a single part. Forming the upper portion 30 as a single member may reduce the overall number of steps required to assemble the autoinjector 2. For example, in some embodiments, no fastening or adhesive steps or materials are required to join the transparent and opaque portions of the housing. By avoiding unnecessary assembly steps, the cosmetic appearance of the autoinjector 2 may be further improved. Additionally, forming the upper portion 30 as a single part may improve the overall structural integrity of the autoinjector 2. Additionally, forming the upper portion 30 as a single part may reduce or eliminate sink marks on the cosmetic surface.

[0038] needle mechanism 5-11, needle mechanism 20 includes a carrier 202 that is movable (e.g., slidable) within housing 3 between a first position (FIG. 6) and a second position (FIG. 7). Needle mechanism 20 may also include a fluid conduit 300 that is attached to carrier 202 and deployed into a user and retracted by driver 320. A shuttle 340 (e.g., a shuttle actuator) may be configured to move driver 320 via deployment gear 360 and retraction gear 362. Shuttle 340 may be coupled to a resilient member (e.g., spring 370). A cover 380 (FIG. 5) may be coupled to carrier 202 to house various components of needle mechanism 20.

[0039] 5, the fluid conduit 300 may extend from a first end 302 to a second end 304. As shown in more detail in FIG. 5A, the first end 302 may include a needle 306 configured to be injected into a user. The needle 306 may include a sharp and / or beveled tip and may generally extend along or parallel to the axis 44. The second end 304 may include a needle 308 that is substantially similar to the needle 306, but may be positioned within the autoinjector 2 to penetrate the cartridge 1302 (shown in FIG. 13 and described in more detail below) and access the medication to be injected into the user. The fluid conduit 300 may include an intermediate portion 310 that includes a first portion extending along or parallel to the axis 40 and a second portion extending along or parallel to the axis 40. The first and second portions of the middle section 310 may be connected by a serpentine section 312 that allows for bending of the fluid conduit 300 and movement of the needle 306 along the axis 44 during deployment and retraction into and from the user. Although a serpentine section 312 is shown, other suitable shapes that allow for bending of the fluid conduit 300 are contemplated, e.g., coils, curves, or other shapes. The serpentine section 312 or similar structure may act as a cantilever when the needle 306 is deployed and / or retracted. The serpentine section 312 may also bias the fluid conduit 300 into the deployed configuration shown in FIG. 5. Once the needle 308 penetrates and establishes fluid communication with the cartridge 1302 (see, e.g., FIG. 14), the medicament may proceed from the cartridge 1302 through the needle 308, the middle section 310, and the needle 306 (pierced through the skin of the user) and into the user. In some examples, the fluid conduit 300 may include only a metal or metal alloy. In other examples, the fluid conduit 300 may be any other suitable material, such as, for example, a polymer or the like. The needle 308 and intermediate section 310 may define a 22 gauge or 23 gauge thin walled needle, while the needle 306 may be a 27 gauge thin walled needle. Other needle sizes, for example, ranging from 6 gauge to 34 gauge, and other needle wall thicknesses, such as regular wall, very thin wall, and ultra thin wall, may also be utilized as desired. The fluid conduit 300 may reduce the amount of material that comes into contact with the agent, reduce bonding and assembly steps, and require less sterilization than conventional devices.

[0040] As shown in FIG. 5B, the needle 308 may be configured to include a needle tip 308a and a side port 308b. The side port 308b may be fluidly connected to the fluid pathway 308c and allow fluid to enter the fluid conduit 300 through the side of the needle 308 rather than through the tip of the needle 308. The rear wall of the side port 308b may be inclined at an angle θ with respect to the longitudinal axis of the fluid pathway 308c. In some embodiments, the angle θ may be between about 20° and 60°, between about 30° and 50°, or about 40°. By configuring the needle 308 in this manner, the needle 308 may be optimized for piercing the primary container of the autoinjector 2, which may be a sealed cartridge or vial. The relative positional relationship of the needle tip 308a and the side port 308b may allow piercing of the seal of the primary container without coring or otherwise cutting a portion of the seal with an opening to the fluid pathway 308c. Thereby, intrusion of particles cored or cut from the seal into the fluid path 308c may be minimized or avoided.

[0041] Needle 306 may be configured substantially similarly to needle 308, as shown in FIG. 5B. Alternatively, in some embodiments, one or both of needles 306 and 308 may be a three-bevel needle, a five-bevel needle, or any other suitable type of needle. In some embodiments, one or both of needles 306 and 308 may be a pencil point needle having a round hole or any other suitable shape hole.

[0042] The carrier 202 may be formed from plastic (e.g., injection molded plastic), metal, metal alloy, etc., and may include a flange 204 with an opening 206, and posts 210, 212. The carrier 202 may also include an opening 216 through which a needle or other fluid conduit may be deployed. The opening 216 may be a slot recessed from an end face of the carrier 202, or in alternative embodiments, the entire periphery of the opening 216 may be formed by the material of the carrier 202. The carrier 202 may also include a driver passage 218. The driver passage 218 may be a slot in the carrier 202 that extends along or parallel to the axis 44. The driver passage 218 may be configured to receive a protrusion of a driver 320, such as, for example, protrusion 330, described in further detail below. The carrier 202 may also include a shuttle passage 220 along which a shuttle 340 may travel, as described in further detail below.

[0043] The carrier 202 may also include a stop 240 configured to engage the shuttle 340. The stop 240 may be a cantilever having a fixed end 241 (FIG. 8) and a free end 242 (FIG. 8). The stop 240 may include an inclined ramp 243 (FIGS. 9 and 12) that, when engaged or pressed by a ramp 1500 (described with reference to FIG. 12), causes the stop 240 to deflect about the fixed end 241. In a first position, the free end 242 may block or otherwise impede movement of the shuttle 340, and in a second configuration, may allow movement of the shuttle 340. The relationship between the stop 240 and the shuttle 340 is described in more detail below in this application.

[0044] The driver 320 includes two racks 322, 324 (shown in FIG. 8 ) that are parallel to one another and disposed on opposite sides of the driver 320. The racks 322, 324 may include teeth and may be configured to engage and drive rotation of the deployment gear 360 and the storage gear 362, respectively. The driver 320 may include a lumen 326 (or track, recess, or other suitable structure) ( FIG. 5 ) configured to receive the needle 306 of the fluid conduit 300. The driver 320 may also include a protrusion 330 ( FIGS. 6 and 7 ) configured to slide within the driver channel 218 of the carrier 202. The protrusion 330 may include a hook-like configuration that can “hook” onto an obstacle 600, as described in more detail below.

[0045] 5, the shuttle 340 may include a rack 342 configured to engage with the gears 360, 362. The shuttle 340 may also include an end face 344 and a recess 346 that extends along the length of the shuttle 340 in the same direction as the rack 342. A slot 348 (FIG. 9) may extend along the length of the recess 346. The slot 348 may extend through the center of the recess 346, or may extend along the entirety or substantially the entirety of the recess 346.

[0046] The shuttle 340 may move along the track 220 from a first start position (FIG. 8) to a second intermediate position (FIGS. 9 and 10), and from the second position to a third final position (shown between the second and third configurations in FIG. 11). As the shuttle 340 moves along the track 220, the rack 342 may first engage the deployment gear 360 and then engage the storage gear 362. At any given time, the rack 342 is always engaged with at most one of the deployment gear 360 and the storage gear 362. In some examples, the rack 342 is not engaged with either the deployment gear 360 or the storage gear 362, such as when the rack 342 is longitudinally disposed between the deployment gear 360 and the storage gear 362. The shuttle 340 may be configured to move only along one axis (e.g., axis 40) and in only one direction along the one axis. The force required to move the shuttle 340 along the track 220 may be provided by the expansion of the spring 370. The spring 370 may be compressed from a resting state, and the expansion of the spring 370 may move the shuttle 340 along the track 220 through the series of positions / configurations described above. At various positions of the shuttle 340, different features of the autoinjector 2 may directly or indirectly inhibit the movement of the shuttle 340. Alternatively, it is contemplated that the spring 370 may be biased to a compressed configuration. In this alternative embodiment, the spring 370 may be expanded from a resting state, and the compression of the spring 370 may move the shuttle 340 along the track 220 through the series of positions / configurations described above.

[0047] The first position of the shuttle 340 shown in FIG. 8 may correspond to an unused, undeployed, and / or new state of the autoinjector 2. In this first position, the driver 320 may be in an undeployed state. The shuttle 340 is maintained in the first position by placing an obstacle 600 in the path of the driver 320 (FIG. 6). The obstacle 600, which may be a shelf of the housing 3 or another suitable blocking device, may prevent the driver 320 from moving by engaging and / or retaining the protrusion 330. Thus, since the driver 320, the deployment gear 360, and the rack 342 are mutually coupled, blocking the driver 320 also prevents the shuttle 340 from moving. The shuttle 340 may be moved from the first position to the second position (or vice versa) by moving the obstacle 600 relative to the carrier 202. In one example, the carrier 202 is moved (e.g., to the left in FIG. 6) while the obstacle 600 remains stationary.

[0048] When the path of the driver 320 is free of the obstacle 600 (FIG. 7), the spring 370 may expand, causing the shuttle 340 to move along the track 220. This linear motion of the shuttle 340 may cause the deployment gear 360 to rotate counterclockwise (or in other examples, clockwise) via the rack 342, and the rotation of the deployment gear 360 may cause the driver 320, via the rack 322 of the driver 320, to move downward along the axis 44. This downward movement of the driver 320 may cause the needle 306 to pierce the skin of the user. In some examples, the driver 320 may be configured to move relative to the carrier 202 only along the axis 44.

[0049] The shuttle 340 may be moved by extension of the spring 370 until the end face 344 of the shuttle 340 abuts the free end 242 of the stop 240 such that the shuttle 340 is maintained in the second position shown in FIGS. 9 and 10. At this point, the free end 242 may prevent further extension of the spring 370 and further movement of the shuttle 340 along the track 220. In this second position, the fluid conduit 300 may be deployed into the user and fluid from the cartridge 1302 may be infused into the user via the needle 306. In addition, while the shuttle 340 is in the second position, the rack 342 may be engaged with the deployment gear 360 to maintain the needle 306 in the deployed configuration. The shuttle 340 may be moved from the second position to the third position by bending of the stop 240 about the fixed end 241 of the stop 240. Further details of this bending are described below with respect to FIGS. 12-14. The bending of stop 240 may allow spring 370 to continue to extend, further biasing shuttle 340 along track 220. In some examples, stop 240 may be received by and / or within recess 346 of shuttle 340, and ramp 243 may slide within slot 348 as shuttle 340 moves from the second position to the third position.

[0050] Movement of the shuttle 340 from the second position to the third position may correspond to retraction of the needle 306 from the user into the housing 3. In particular, the rack 342 may engage and rotate the storage gear 362 in the same direction that the deployment gear 360 was rotated (e.g., counterclockwise or clockwise). The rotation of the storage gear 362 may urge the driver 320 back to the retracted position via the rack 324. The shuttle 340 may reach the third position, in which the driver 320 is fully retracted, when the end face 344 of the shuttle 340 engages a wall of the carrier 202, when the free end 242 of the stop 240 reaches the end of the recess 346, and / or when the spring 370 reaches a rest state.

[0051] In some embodiments, when the driver 320 returns from the deployed state to the retracted state, it may be prevented from emerging from the retracted state. As a result, the needle 306 is prevented from being redeployed into the user. In this configuration, the autoinjector 2 may be a disposable device (e.g., discarded after completing one injection). In other embodiments, the autoinjector 2 may be reset and reused. Additionally, the deployment gear 360 and retraction gear 362 may be the only rotating gears located within the autoinjector 2 in some examples.

[0052] Piercing Systems and Sterile Connectors 13 and 14 show features of a piercing system 1300 of the autoinjector 2. Further details of an exemplary piercing system can be found in U.S. Patent Application Publication No. 2016 / 0262984 to Arnott et al., published September 15, 2016, which is incorporated herein by reference in its entirety. The piercing system 1300 includes a primary container, which may be a cartridge 1302 having a first end 1304 and a second end 1306. The primary container may alternatively be a chamber, a syringe, a vial, a flexible bladder, or other suitable fluid-containing structure.

[0053] The cartridge 1302 may be open at a first end 1304 and include a cavity 1308 extending toward a second end 1306. The second end 1306 may include a neck 1310 with a cap 1312 engaging the neck 1310 to close the second end 1306. A septum 1314 may be disposed between the cartridge 1302 and the cap 1312 to aid in closing the second end 1306 and to allow a needle 308 (e.g., a fixed needle) to be inserted into the cartridge 1302. The cavity 1308 may be closed at the first end 1304 by a piston 1316.

[0054] The cartridge 1302 may have a capacity of 5 mL in some examples, but any other suitable volume (e.g., 1 mL to 50 mL, or 2 mL to 10 mL, or 3 mL to 6 mL, or 2 mL to 5 mL, or another suitable range) may also be utilized depending on the medication to be delivered. In other examples, the cartridge 1302 may have a capacity of 1 mL or more, or 2 mL or more, or 3 mL or more, or 4 mL or more, or 5 mL or more, or 10 mL or more, or 15 mL or more. The cartridge 1302 may contain and store medication for injection into a user and may help maintain sterility of the medication. The cartridge 1302 may have a neck with a diameter of 13 mm, a length of 45 mm, and an inner diameter of 19.05 mm. These values ​​are merely exemplary and other suitable dimensions may be utilized as needed. In some examples, the cartridge 1302 may be formed using conventional materials and may be shorter than existing devices, which may help make the autoinjector 2 cost-effective and keep the autoinjector 2 small. The cartridge 1302 may be a shortened version of the ISO 10 mL cartridge.

[0055] The septum 1314 may include an uncoated bromobutyl material or another suitable material. The piston 1316 may include a fluoropolymer coated bromobutyl material and may include a conical nose 1316a to help reduce dead volume within the cartridge 1302. The piston 1316 may include one or more rubber materials such as, for example, halobutyl (e.g., bromobutyl, chlorobutyl, fluorobutyl) and / or nitrile, among other materials.

[0056] The piercing system 1300 may also include a top 1354 disposed at the second end 1306. The top 1354 may include a base 1355 disposed to cover the septum 1314 and the opening of the cartridge 1302. The top 1354 may include a chamber 1356 extending from the base 1355 in a direction away from the piston 1316. The chamber 1356 defines a cavity 1357 and includes an opening 1358 in communication with the cavity 1357. In some embodiments, the top 1354 may be integral with the septum 1314 (e.g., a unitary or one-piece structure). In an alternative embodiment (not shown), the top 1354 is provided on the fluid conduit 300 or initially assembled on the fluid conduit 300 and is not directly placed on or with the cartridge 1302 and / or is not integrated with the septum 1314.

[0057] A portion of the fluid conduit 300, such as a needle 308, tube, or the like, may extend into the cavity 1357 through an opening 1358 in the chamber 1356, but not through the base 1355 in the pre-activated state. The opening 1358 may be pre-formed or may be formed by the penetration of the needle 308 through the chamber 1356. The opening 1358 in the chamber 1356 may form a sterile sliding seal around the needle 308 to prevent migration of pathogens or other contaminants into the cavity 1357. The needle 308 may move relative to the top 1354 without breaking the sterile seal therebetween. The cavity 1357 may be sterile or aseptic such that the inner surfaces of the cavity 1357 and the needle 308 are sterile. In another embodiment, the cavity 1357 may be sterilized after the needle 308 is inserted into the cavity 1357 through the opening 1358. In an alternative embodiment, a convoluted flexible (e.g., rubber) bellows or bladder member, rather than the top 1354, may form the cavity 1357 and allow translation of the cartridge 1302 relative to the needle 308 (or vice versa). The flexible member may also seal the needle 308 or form the cavity 1354 around the needle 308 after sterilization.

[0058] The piston 1316 may be coupled to a translation mechanism 1366 configured to translate the piston 1316 and the cartridge 1302 in a direction toward the second end 1306. The movement of the piston 1316 toward the second end 1306 causes the piston 1316 to act against the contents (e.g., medication, drug) within the cartridge 1302, ultimately transmitting a force to the second end 1306 of the cartridge 1302, moving the cartridge 1302 along the longitudinal axis 40. The translation mechanism 1366 may include a 12 mm motor with a 5-stage gear reducer (360:1). The translation mechanism 1366 may have spring contacts that form an electrical connection with an associated printed circuit board (e.g., the first electronics board 1402). The motor may be configured to generate a torque of approximately 136 mN*m at 36 rpm. These design parameters of the motor are merely exemplary, and any other suitable motor may be utilized.

[0059] The translation mechanism 1366 may include a lead screw mechanism coupled to the piston 1316 that extends axially upon relative rotation about the longitudinal axis 40. The telescopic lead screw may have a 7° / 45° sawtooth thread profile with a 100 N power output, a 20 mm stroke, and a 0.75 mm pitch. Materials for the lead screw mechanism may include acetal and polybutylene terephthalate. The lead screw mechanism may extend into the piston 1316 to reduce dead space behind the piston 1316. Although the piston 1316 is shown in FIGS. 13 and 14 with longitudinally spaced threads, in some examples, such threads may not be present. In another exemplary embodiment (not shown), the translation mechanism 1366 may include a manually engageable surface or member that is manually operated by a user to move the piston 1316. For example, the drilling system 1300 may include a cartridge or plunger coupled to the rear of the piston 1316. In another exemplary embodiment (not shown), the translation mechanism 1366 may include a pneumatic or hydraulic drive member that is actuated or initiated by a user to move the piston 1316. The drive member may be in the form of, for example, an expansion bellows, an expansion bladder, an expansion diaphragm, or a sliding seal or piston. Direct pneumatic or hydraulic pressure may provide the force necessary to move the piston 1316.

[0060] The drilling system 1300 also includes a collar 1390 coupled or secured to the second end 1306. The collar 1390 may include a plurality of circumferentially spaced fingers 1392 that engage and encircle the neck 1310. The collar 1390 may be fixed or otherwise coupled to the second end 1306. The collar 1390 may include a wall 1390a that extends at least partially around the neck 1310, the opening of the second end 1306, the cap 1312, the septum 1314, and / or the top 1354. The wall 1390a of the collar 1390 may be disposed radially or laterally outward of the neck 1310 and extend longitudinally beyond the neck 1310, the cap 1312, and the septum 1314.

[0061] In the pre-actuated state of the drilling system 1300 shown in FIG. 13 , an end 1393 of the collar 1390 may engage a corresponding radially or laterally inwardly extending cam, latch, or actuation portion 1394 of a driver retaining member 1395. The retaining member 1395 may be slidable relative to the collar 1390. The collar 1390 and the retaining member 1395 may be configured such that in the pre-actuated state or arrangement shown in FIG. 13 , at least a portion of the cam or actuation portion 1394 of the retaining member 1395 is disposed directly behind a retaining portion 1399 of a driver 1398 that is slidable within the retaining member 1395. A wall 1391 of the driver 1398 may extend into and through an end cap portion 1396 of the retaining member 1395 into an interior portion of the retaining member 1395, and the retaining portion 1399 of the driver 1398 may extend radially outward from the wall 1391. In some embodiments, the wall 1391 of the driver 1398 can be substantially cylindrical and the retaining portion 1399 of the driver 1398 can be a flange extending around the end of the wall 1391 .

[0062] In a pre-actuated state of the drilling system 1300, an elastically deformed biasing member or resilient member 1397 may be disposed between a cap portion 1396 of the retaining member 1395 and a retaining portion 1399 of the driver 1398. The biasing member 1397 may exert a force on the driver 1398 in the pre-actuated state of the drilling system 1300 acting in a direction toward the cartridge 1302. The biasing member 1397 may be any member effective in applying a force in the pre-actuated state and then releasing such force upon actuation, as described below with reference to FIG. 14 . In some embodiments, the biasing member 1397 may be a conical or flat spring.

[0063] The needle 308 of the fluid conduit 300 may be secured or coupled to the driver 1398 such that the fluid conduit 300 moves with the driver 1398. In a pre-activated state of the piercing system 1300, the needle 308 may be disposed within the sterile cavity 1357, but not through the base 1355 of the top 1354, the septum 1314, and / or within the cavity 1308 of the cartridge 1302.

[0064] In some embodiments, instead of the cavity 1357, the needle 308 may be disposed within the plug when the piercing system 1300 is in a pre-activated state. The plug may be a solid plug without holes, cavities, or openings and may be formed from a first rubber material. The first rubber material may be permeable to a sterilizing gas, such as, for example, ethylene oxide or vaporized hydrogen peroxide. The first rubber material may include one or more of isoprene, ethylene propylene diene monomer (M class) rubber (EPDM), and styrene butadiene, among others. The permeability of the first rubber material to the sterilizing gas may allow the needle 308 to be sterilized prior to use when disposed within the plug. The plug may be molded around the needle 308 such that the needle 308 penetrates the plug.

[0065] To move the drilling system 1300 from the pre-actuated state of FIG. 13, the translation mechanism 1366 may be actuated to move the piston 1316 toward the second end 1306 and translate the cartridge 1302 along the longitudinal axis 40 toward the driver 1398. Because the needle 308 is not yet in fluid communication with the cartridge 1302, actuation of the translation mechanism 1366 applies pressure against the fluid contained within the cartridge 1302, which is then applied to the cartridge 1302 itself. This pressure also causes the end 1393 to push against the actuating portion 1394, deflecting it radially outward. Without the actuating portion 1394 blocking its path, the retention portion 1399 and needle 308 are moved toward the cartridge 1302 by the expansion of the biasing member 1397. The driver 1398 may be coupled to the flange 204 of the carrier 202, such that this movement of the driver 1398 towards the cartridge 1302 may also move the carrier 202 in the same direction. This movement corresponds to the movement of the carrier 202 relative to the housing 3 in Figures 6 and 7, which allows the projection 330 to pass the obstruction 600 to inject the needle 306.

[0066] Movement of the needle 308 toward the second end 1306 of the cartridge 1302 also causes the needle 308 to pierce the base 1355 of the top 1354, the septum 1314, and the cavity 1308, placing the needle 308 in fluid communication with the contents of the cartridge 1302. Once the needle 308 is in fluid communication with the cartridge 1302, further movement of the piston 1316 toward the second end 1306 urges fluid through the needle 308 and the remainder of the fluid conduit 300. In some embodiments, the piercing system 1300 may be configured such that, after actuation, no more of the needle 308 extends into the cavity 1308 than is already disposed within the sterile cavity 1357. This may help prevent contamination of the contents of the cartridge 1302 with non-sterile portions of the needle 308.

[0067] The biasing member 1397 can be configured to expand such that the fluid conduit 300 pierces the apex 1354 and / or the septum 1314 at a high rate, such as a rate of at least about 10 mm / sec, or at least about 40 mm / sec. The relatively rapid piercing of the apex 1354 and / or the septum 1314 by the biasing member 1397 can help prevent leakage of the contents of the cavity 1308, which may be under pressure by the piston 1316.

[0068] After the drug is delivered to the user through the needle 306, the needle 306 may be automatically withdrawn from the user. With reference to FIGS. 12-14, the translation mechanism 1366 may be operated in a reverse mode such that the rotation of the lead screw is in the opposite direction compared to the insertion step. This reverse rotation may move the piston 316 back toward the first end 1304 and may also move the cartridge 1302 in the opposite direction along the axis 40 (compared to during the delivery of the fluid and the insertion of the needle 306). The movement of the cartridge 1302 in the opposite direction may cause the ramp 1500 of FIG. 12 (mounted on the wall 1391) to press against the ramp 243 of the stop 240. This may deflect the stop 240 about the fixed end 241 of the stop 240 in the direction of the arrow 240a, allowing the shuttle 340 to move from its second position to its third position and retract the needle 306 as described above. In this manner, both withdrawal and insertion of the needle into the patient can be accomplished with a single spring within the device.

[0069] It is further contemplated that the fluid conduit 300 may be the only fluid conduit of the autoinjector 2 configured to be in fluid communication with the cartridge 1302. Thus, medication from the cartridge 1302 may be deployed into a user only through the fluid conduit 300 during normal operation of the autoinjector 2. Additionally, the needle 306 may be the only needle of the autoinjector 2 configured to be deployed into a patient. In this manner, a single piece of metal or plastic may be used to transport fluid from the cartridge 1302 to the patient.

[0070] Locking parts (drop pins) 16A-16D, the autoinjector 2 may include a locking component 1610. As shown in FIG. 16A, the locking component 1610 may include a locking portion (e.g., a protruding portion) 1612 having a curved surface 1614, and may further include a cover portion 1616. The cover portion 1616 may be shaped to match the tissue engaging surface 4 of the autoinjector 2, as shown in FIG. 16D. The cover portion 1616 and the tissue engaging surface 4 may be concave to receive an anatomical portion 1600 of a user. The anatomical portion 1600 may be, for example, a thigh, buttocks, arm, back, or any other part of the body suitable for injection. The locking portion 1612 may be connected to the cover portion 1616. In some embodiments, the locking component 1610 may be formed as a single piece such that the locking portion 1612 and the cover portion 1616 are integrally connected. The locking component 1610 may be formed from any suitable rigid or semi-rigid material. The locking component 1610 may be formed from, for example, acrylonitrile butadiene styrene (ABS) and may further have a frosted, transparent appearance indicating that the locking component 1610 is disposable.

[0071] As shown in FIGS. 16B-16C, the locking component 1610 may be disposed on or adjacent to the tissue engaging surface 4 of the autoinjector 2 such that the locking portion 1612 may extend into the autoinjector 2. The locking component 1610 may further be disposed on or adjacent to the liner 12a, which may initially cover the adhesive patch 12 prior to use of the autoinjector 2. The locking component 1610 may be positioned relative to the liner 12a such that upon removal of the liner 12a from the adhesive patch 12, the locking component 1610 may also be removed from the tissue engaging surface 4. The locking portion 1612 may extend into the autoinjector 2 through a locking opening 1630 formed in the tissue engaging surface 4. When the locking component 1610 is disposed on or adjacent to the tissue engaging surface 4, the cover portion 1616 may be attached to the tissue engaging surface 4 via an adhesive disposed between the cover portion 1616 and the tissue engaging surface 4. The locking component 1610 may be disposed on or adjacent to the tissue engaging surface 4 so as to be selectively removable by a user.

[0072] 16C-16D , when the locking component 1610 is disposed on or adjacent to the tissue engaging surface 4, the locking portion 1612 may extend into the autoinjector 2 to prevent movement of one or more internal mechanisms of the autoinjector 2. For example, when the locking component 1610 is disposed on or adjacent to the autoinjector 2, the locking portion 1612 may extend into the autoinjector 2 such that the locking portion 1612 engages one or more internal components of the autoinjector 2 to prevent those components from moving and / or actuating.

[0073] 16D, when the locking component 1610 is disposed on or adjacent to the tissue engaging surface 4, the locking portion 1612 may extend into the autoinjector 2 to be disposed within the piercing system 1300. As previously described herein, the collar 1390 may be coupled or secured to the second end 1306 of the cartridge 1302. Also, as previously described herein, when the piercing system 1300 moves from a pre-actuated state, the cartridge 1302, and thus the collar 1390, may translate in a direction parallel to the longitudinal axis of the cartridge 1302 toward the retaining portion 1399. When the locking portion 1612 extends into the autoinjector 2 and is adjacent to the collar 1390, the locking portion 1612 may prevent the cartridge 1302 from translating toward the retaining portion 1399 or otherwise prevent the cartridge 1302 and collar 1390 from applying a force against the actuation portion 1394. Thus, even if the motor is actuated in some manner while the locking portion 1612 is disposed in its locked position, fluid communication between the needle 308 and the cartridge 1302 cannot be established and the needle 306 cannot be deployed outside the housing 3. Furthermore, when in the locked position, the locking portion 1612 may prevent the cartridge 1302 from moving towards the needle 308, thereby preventing deflection of the actuating portion 1394 and, as a result, the retaining portion 1399 and the needle 308 from moving towards the cartridge 1302. If the autoinjector 2 is dropped or subjected to vibration, the locking portion 1612 may further prevent the piercing system 1300 from moving from the pre-actuated state, thereby preventing the cartridge 1302 from being pierced by the needle 308.

[0074] When the locking component 1610 is disposed on or adjacent to the tissue engaging surface 4, the locking component 1610 may further act as a spacer between the user's skin and the tissue engaging surface 4. For example, the locking component 1610 may have a thickness such that the touch sensor 1410, described in more detail below, is unable to detect the user's skin, thereby avoiding inadvertent actuation of the autoinjector 2. The locking component 1610 may have a thickness of, for example, about 1 mm to about 5 mm, or about 3 mm.

[0075] The locking component 1610 may thus function as an effective safety mechanism to prevent inadvertent actuation of the autoinjector 2. When the locking component 1610 is positioned on or adjacent to the tissue engaging surface 4, the locking portion 1612 may prevent various internal components of the autoinjector 2 from moving. If the autoinjector 2 is dropped to the floor prior to use, for example, the locking component 1610 may prevent inadvertent puncturing of the cartridge 1302 and / or inadvertent initiation of an injection sequence. The locking component 1610 may also prevent such movement and / or inadvertent initiation of an injection sequence if the autoinjector 2 is subjected to vibration during shipping.

[0076] When the user wishes to use and / or is ready to use the autoinjector 2, the user may separate the locking component 1610 from the tissue engaging surface 4, thereby removing the locking portion 1612 from the locking opening 1630. The user may, for example, peel the cover portion 1616 from the tissue engaging surface 4. Alternatively, the user may peel the liner 12a from the adhesive patch 12, thereby removing the locking component 1610 from the tissue engaging surface 4. When separating the locking component 1610 from the tissue engaging surface 4, the curved surface 1614 may allow the locking portion 1612 to swing within the locking opening 1630, thereby allowing the locking portion 1612 to be easily removed from the locking opening 1630. With the locking portion 1612 removed from the locking opening 1630, the autoinjector 2 may be in a state ready to be used such that, for example, an injection sequence may be initiated.

[0077] 16E and 16F show a locking part 1610 according to some embodiments. As shown in FIG. 16E and 16F, the locking part 1610 may have an increased width (relative to the depiction of the locking part 1610 in FIG. 16A-16C) to ensure that the locking part 1610 extends over the touch sensor 1410 when the locking part 1610 is placed on the autoinjector 2. Additionally, the locking part 1610 may have a ribbed structure and may include a void or recess 1618 and a hinge 1620. The void 1618 may prevent conduction of a capacitive electric field between the user's skin and the touch sensor 1410 when the autoinjector 2 is placed near the user with the locking part 1610 in place. The hinge 1620 may allow the locking part 1610 to flex when the locking part 1610 is peeled away from the autoinjector 2. In some embodiments, a removable cover other than and / or separate from the locking part 1610 may extend over the touch sensor 1410 to prevent inadvertent skin detection.

[0078] electronic equipment 4A illustrates a control system 1400 of the autoinjector 2. The control system 1400 may include components disposed on a first electronics board 1402 and a second electronics board 1404, and may include a power supply 1406. The first electronics board 1402 may include a controller 1408, an activation switch 1409, a touch sensor 1410, a needle insertion switch 1412, and an emitter 1414. The second electronics board 1404 may include a detector 1416, an audio module 1418, a vision module 1420, and a tactile module 1422. Although FIG. 4A illustrates the audio module 1418, the vision module 1420, and the tactile module 1422 as being included on the second electronics board 1404, in some embodiments, one or more of the aforementioned modules may be included on the first electronics board 1402. One or more of the components of the first electronics board 1402 and the second electronics board 1404 may be operably coupled to a controller 1408 and powered by a power source 1406. The controller 1408 may also be operably coupled to a translation mechanism 1366 and configured to control operation of the translation mechanism 1366 to initiate and control needle insertion and retraction, as described above. The translation mechanism 1366 may be coupled to the first electronics board 1402 via one or more spring contacts during the final assembly step in which the cartridge 1302 is inserted into the housing 3. As previously described herein, the translation mechanism 1366 may include a motor, gearing, and lead screw mechanism.

[0079] Most of the assembly of the autoinjector 2 may take place, for example, on an assembly line at a manufacturing facility. The two device halves (or parts) may then be shipped to a drug filling facility or a final assembly facility. In fact, the two separate parts 1490, 1492 do not have to be the same size, as shown in FIG. 4B. Once a drug vial, e.g., cartridge 1302, is filled with a drug or other substance, the cartridge 1302 may be assembled with the remaining parts of the autoinjector 2. For example, the two device halves (parts 1490, 1492) may be assembled with the filled drug cartridge 1302. In one example, the part 1490 and the translation mechanism 1366 may be snapped into place behind the cartridge 1302. The part 1490 may be part of a housing 3 that includes a base or module configured to house the translation mechanism 1366 and its associated electronics. The portion 1492 may be part of a housing 3 that includes substantially all of the other components described herein, including, for example, the needle mechanism, sterile connector, and piercing mechanism described herein. In this example, the electrical connection of the motor of the translation mechanism 1366 needs to be made during snap-fit ​​of the translation mechanism 1366 behind the cartridge 1302 (i.e., during the assembly step where the portions 1490 and 1492 and the cartridge 1302 are combined to form a complete and functional autoinjector 2). To accommodate such electrical connection, the drive system of the translation mechanism 1366 may include one or more spring contacts 1494 (see FIG. 4C ) that contact pads 1495 (see also FIG. 4C ) on the first electronics board 1402 upon assembly. Although not shown in FIG. 4C , the drive system of the translation mechanism 1366 may include additional spring contacts that may contact additional pads on the first electronics board 1402 upon assembly. Such additional spring contacts and additional pads may serve to connect additional components of the translation mechanism 1366, such as a tachometer, motor encoder, or other sensors or devices, to the first electronics board 1402. Thus, connection of the translation mechanism 1366 to the first electronics board 1402 (including the controller 1408) may be made without loose wires or other similar structures.

[0080] Such an assembly process may be relatively simpler than simple devices (e.g., autoinjectors) that have relatively more complex final assembly processes. As a result, the contemplated assembly processes described herein may lead to reduced labor costs.

[0081] In some embodiments, the autoinjector 2 may include a single (i.e., only one or exactly one) electronics board 1710 as shown in FIG. 17 and FIG. 17A on which the components of the control system 1400 described hereinabove may be located. As shown in FIG. 17A, the electronics board 1710 may include a first board segment 1712 and a second board segment 1714. The first board segment 1712 and the second board segment 1714 may be physically and electrically connected via a flexible segment 1716. The flexible segment 1716 may be, for example, a ribbon cable, a flexible conductive board, or the like. In some embodiments, the flexible segment 1716 may be machined thin enough to flex and formed of a fiberglass board, sometimes referred to as "semi-flex". In some embodiments, the flexible segment 1716 may be formed of a flexible polymer. The flexible polymer may be formed by a process sometimes called "rigid-flex" in which a sandwich of a first portion of fiberglass, flexible polymer, and a second portion of fiberglass is first formed. The first and second portions of fiberglass can then be removed, leaving a thin flexible polymer portion.

[0082] The electronics board 1710 may include one or more brackets 1720 for mounting or otherwise securing the electronics board 1710 to an interior of the autoinjector 2. The first substrate segment 1712 may further include a notch 1718. The notch 1718 may be positioned such that the first substrate segment 1712 may be positioned to allow a needle to pass through the notch 1718 upon deployment.

[0083] In some embodiments, the first substrate segment 1712 may correspond to the first electronics board 1402 and the second substrate segment 1714 may similarly correspond to the second electronics board 1404, each as previously described herein. By connecting the first substrate segment 1712 and the second substrate segment 1714 via the flexible segment 1716, the first substrate segment 1712 may be positioned adjacent to the tissue engaging surface 4 of the autoinjector 2, while the second substrate segment 1714 may be positioned on the opposite side of the autoinjector 2 towards the upper portion 30 of the housing 3. Thus, a single electronics board 1710 may be utilized to both connect components located on the tissue engaging surface 4 side and components located on the upper portion 30 side. Such a configuration may facilitate assembly of the autoinjector 2 by eliminating the need for complex wiring or soldering.

[0084] 17, the electronics board 1710 may be disposed within the housing 3. The first board segment 1712 may be disposed adjacent to the tissue engaging surface 4, and the second board segment 1714 may be disposed on the opposite side of the autoinjector 2 (e.g., rearward of the first board segment 1712 in FIG. 17). The flexible segment 1716 may be bent or folded to maintain a connection between the first board segment 1712 and the second board segment 1714 in such position.

[0085] The touch sensor 1410 may be incorporated in or on the first substrate segment 1712 of the electronics board 1710. To allow for proper detection of the user's skin, the touch sensor 1410 and the first substrate segment 1712 may be disposed proximate to the tissue engaging surface 4 of the housing 3. The tissue engaging surface 4 of the housing 3, or a portion of the tissue engaging surface 4 adjacent to the touch sensor 1410, may be sufficiently thin such that an electric field of detectable magnitude may be formed between the touch sensor 1410 and the user's skin. In some embodiments, the portion of the tissue engaging surface 4 adjacent to the touch sensor 1410 may be less than about 2 mm, about 1 mm, or less than about 1 mm. Additionally, the portion of the tissue engaging surface 4 adjacent to the touch sensor 1410 may be made of a solid material, such as plastic. By forming a portion of the tissue engaging surface 4 adjacent the touch sensor 1410 from a solid material, as opposed to a ribbed, cored, or hollow material, the dielectric constant between the user's skin and the touch sensor 1410 can optimize the responsiveness of the touch sensor 1410.

[0086] Additionally, the touch sensor 1410 may be positioned in or on the electronics board 1710 such that it is adjacent or near the opening 6 through which the needle may be deployed. By positioning the touch sensor 1410 adjacent or near the opening 6, the likelihood that the touch sensor 1410 may detect the user's skin when the autoinjector is properly positioned is increased. Furthermore, the curvature of the tissue engaging surface 4 may reduce the likelihood that the touch sensor 1410 may misinterpret a flat surface, such as a table top, as the user's skin by creating a space between the touch sensor 1410 and the flat surface.

[0087] Incorporating the touch sensor 1410 into or on the electronics board 1710 may eliminate the need for one or more wires and / or other circuitry connecting the touch sensor 1410 to a separate electronics board, which may simplify assembly of the autoinjector 2 and reduce the cost of the autoinjector.

[0088] The electronics board 1710 may be positioned adjacent the tissue engaging surface 4 such that the electronics board 1710 may include a notch to allow a needle to penetrate the electronics board 1710 and subsequently be deployed through the opening 6. Additionally, the electronics board 1710 may be positioned such that the touch sensor 1410 is directly adjacent the opening 6 and such that there is no gap between the end of the touch sensor 1410 and the opening 6. Alternatively, the electronics board 1710 may be positioned such that a gap exists between the end of the touch sensor 1410 and the opening 6, with the gap having a maximum width of, for example, 5 mm, 2 mm, or 1 mm.

[0089] The controller 1408 may be configured to accept information from the systems and system components described above, process the information according to various algorithms to generate control signals for controlling the internal mechanisms of the autoinjector 2, including the translation mechanism 1366. Examples of such algorithms are described below with reference to Figures 18 and 20-23. The processor may accept information from the systems and system components, process the information according to various algorithms, and generate information signals that may be directed to an audio module 1418, a visual module 1420, a tactile module 1422, or other indicators, for example, on the second electronics board 1404, to inform the user of system status, component status, treatment status, or any other useful information being monitored by the system. The processor may be a digital IC processor, an analog processor, or any other suitable logic or control system that executes the control algorithms.

[0090] As described above with respect to FIGS. 3A and 3B, the activation switch 1409 may be a mechanical plunger-type switch that extends away from the tissue-engaging surface 4 of the autoinjector 2. The activation switch 1409 may include an electrical circuit that is intact unless the activation switch 1409 is pressed. For example, when the autoinjector 2 is attached to the skin of a user, the switch 1409 may be pressed, interrupting the electrical circuit to indicate to the controller 1408 that the autoinjector 2 should be activated. To conserve power, components of the autoinjector 2 may be in an idle or sleep mode until the switch 1409 is activated. In yet another example, the autoinjector 2 may not receive any power until the switch 1409 is activated, and deactivation of the switch 1409 may completely interrupt power to the autoinjector 2. Although a mechanical plunger-type switch is disclosed, any other suitable mechanism for activating the autoinjector 2 may be utilized, including, for example, a button pressed by the user, an audio signal, and a wireless signal from another electronic device.

[0091] The touch sensor 1410 may be configured to assist the controller 1408 in determining whether the autoinjector 2 is properly placed on the user's skin. In one example, the touch sensor 1410 may be a capacitive sensing electrode or any other device configured to distinguish contact with the skin against other materials, such as, for example, wood, plastic, metal, or another material. When the skin is in the vicinity of the capacitive sensing electrode, a signal indicative of such contact may be transmitted to the controller 1408. Thus, the touch sensor 1410 may function to verify that the autoinjector 2 is properly placed on the user's skin, even when the switch 1409 is pressed. The touch sensor 1410 may include a capacitive sensing electrode coupled to the first electronics board 1402 and the interior of the housing 3. The housing 3 and the adhesive patch 12 may function as an overlay (insulator) that acts as a dielectric between the user's skin and the capacitive sensing electrode. Alternatively, the touch sensor 1410 may be integrated into or on the electronics board 1710, as previously described herein, such that the capacitive sensing electrodes are also integrated into or on the electronics board 1710. Contact of portions of the housing 3 and / or adhesive patch 12 near the capacitive sensing electrodes may increase the capacitance of the electrodes, for example, by about 1 to about 10 pF, indicating placement of the autoinjector 2 on the skin surface.

[0092] The needle insertion switch 1412 may be configured to send a signal to the controller 1408 that the needle 306 has been deployed into the user. For example, with reference to FIG. 15, the needle insertion switch 1412 may include a curved cantilever 1510 that includes a first contact 1512. The needle insertion switch 1412 may also include a second contact 1514. The first contact 1512 may be positioned to make electrical contact with the second contact 1514 when the needle 306 is deployed into the user. During deployment of the needle 306, the driver 320 may move downward along the axis 44, deflecting the curved cantilever 1510 and the first contact 1512 toward the second contact 1514. When the first contact 1512 and the second contact 1514 connect to each other, a signal may be sent to the controller 1408 indicating that the needle 306 has been successfully deployed into the user. Separation of the first contact 1512 and the second contact 1514 may indicate that the needle 306 has been retracted away from the user.

[0093] The emitter 1414 and detector 1416 may operate as a light interrupt sensor or photointerrupter to allow the controller 1408 to determine the status of the autoinjector 2. The emitter 1414 may be a light emitting diode (LED) or other suitable light emitting device, and the detector 1416 may be, for example, a phototransistor configured to receive light emitted by the emitter 1414. In one example, the emitter 1414 may emit infrared light, although other suitable wavelengths of light may be used. The use of infrared light may help reduce interference from external light.

[0094] As shown in FIG. 13B, the emitter 1414 and the detector 1416 may be positioned opposite one another within the housing 3 to allow the light beam 1430 to pass from the emitter 1414 through the cartridge 1302 to the detector 1416. The cartridge 1302 and any fluid contained therein may be at least partially transparent to the beam 1430 such that the beam 1430 may pass through the cartridge 1302 and its contents. When the piston 1316 is moved toward the second end 1306 during drug delivery (see FIGS. 13 and 14), the piston 1316, and in particular the shoulder of the piston 1316, may block the beam 1430. When the detector 1416 is unable to detect the beam 1430, a signal may be sent to the controller 1408, which may interpret the signal as indicating the end of the injection (e.g., that all of the drug contained within the cartridge 1302 has been expelled). In some examples, the refracted path of the beam 1430 may be taken into account when positioning the emitter 1414 and the detector 1416 relative to one another. For example, the beam 1430 may be refracted as it passes through the cartridge 1302 and any fluid contained therein, so the emitter 1414 and the detector 1416 may be offset from one another accordingly. In addition, the emitter 1414 and the detector 1416 may be offset from the center of the housing 3 such that a shoulder of the piston 1316 may block the beam 1430. In at least some examples, an optical interruption sensor or similar mechanism may help to avoid false positives in the event of a drive train failure. That is, an optical switch may help the controller 1408 determine with greater accuracy than other mechanisms that the injection was not completed.

[0095] The audio module 1418 may include a speaker or the like for providing audio feedback to the user. An opening in the housing 3 may facilitate the transmission of sound from the audio module 1418 to the user. The audio module 1418 may generate tones or other sounds at the beginning and end of an injection and / or to indicate any other benchmarks during an injection, such as, for example, errors. The visual module 1420 may include one or more LEDs or similar devices for providing visual feedback to the user. The visual module 1420 may include different colored LEDs to provide various messages to the user. For example, multiple blue LEDs arranged in a ring may be used to indicate the progress of an injection over time, one or more green LEDs may be used to indicate the completion of an injection, and a red LED may be used to indicate an error to the user. Other suitable colors, combinations, and / or numbers of LEDs may be used in various examples. For example, a combination of red, blue, and purple LEDs may be utilized. In one configuration, eight LEDs may be arranged in a circle having a diameter of about 26.5 mm, or a diameter of about 10.0 mm to about 40.0 mm. This exemplary number and arrangement of LEDs is not intended to be limiting, and it should be understood that any number and / or arrangement of LEDs may be used. The LEDs may be activated sequentially around a circle to indicate the progress of an injection (e.g., in a progression ring arranged similar to a clock, see, e.g., LED 52 in FIG. 4B). The controller 1408 may also be configured to receive feedback from various sensors and readjust the rate at which the various LEDs are activated based on the feedback from the sensors. For example, the LEDs in the progression ring may be activated in three or more operational phases, including, for example, an injection sequence activation phase, an injection phase, and a storage phase. One skilled in the art will recognize that the autoinjector 2 may have more or less operational phases than the three operational phases described above. While there may be an expected time to complete each phase, there may be some variability in the time actually experienced by the autoinjector 2 in any of the aforementioned operational phases.Algorithms may be utilized, for example, to help avoid premature activation of LEDs if a particular stage is completed sooner than expected, or to halt progression along the ring if a particular stage is taking longer than expected. At any given time, the algorithm may divide the estimated time remaining until drug delivery is completed by the number of unactivated LEDs in the progression ring to determine the rate at which the remaining LEDs in the progression ring should be activated.

[0096] For example, prior to the injection sequence activation phase, the LEDs may be activated at a rate equal to the estimated time for the entire drug delivery process (e.g., the estimated time to complete all of the injection sequence activation phase, injection phase, and storage phase) divided by the total number of unactivated LEDs in the progression ring. In other words, the estimated time for the entire drug delivery process may be divided by the total number of LEDs in the progression ring minus the number of LEDs that have already been activated. Thus, for example, if one LED has already been activated, the estimated time for the entire drug delivery process may be divided by one less than the total number of LEDs in the progression ring.

[0097] After completion of the injection sequence activation phase, the LEDs may be activated at a rate equal to the sum of the estimated time to complete the remaining phases (e.g., the injection phase and the storage phase) divided by the number of unlit LEDs in the progression ring. After completion of the injection phase, the LEDs may be activated at a rate equal to the estimated time to complete the storage phase divided by the number of unlit LEDs.

[0098] In some embodiments, a subset of the LEDs may be used to indicate the progression of the injection stages. For example, in an embodiment having eight LEDs disposed on the housing of the autoinjector 2, the first LED may be illuminated to indicate needle insertion. The second through seventh LEDs may then be illuminated in sequence to indicate the progression of the injection stages. Finally, the eighth LED may be illuminated to indicate needle retraction. Although an exemplary configuration of LEDs and corresponding logic has been described, it should be understood that the quantity of LEDs for each stage of the injection process may be varied as desired.

[0099] The vision module 1420 may also include a display screen, touch screen, or other suitable device to provide one-way or two-way communication with the user. The vision module 1420 may be viewable by the user from outside the housing 3 through a window in the housing 3. The tactile module 1422 may include, for example, a haptic motor configured to generate vibrations that can be felt by the user. The vibrations may signal the start and end of an injection and / or may help provide additional information to the user.

[0100] The controller 1408 may be coupled to a wireless communication module and an antenna. The wireless communication module may be configured to transmit data from the controller 1408 to, for example, a mobile device, a computer, a mobile phone, etc. The wireless communication module may be configured to transmit information via one or more wireless modalities, such as, for example, Bluetooth, Bluetooth low energy (BLE), Near Field Communication (NFC), infrared, cellular networks, and wireless networks, among others. The antenna may be any suitable device configured to assist the wireless communication module in data transmission and / or amplification. Thus, the controller 1408 may be configured to transmit diagnostic information of the user and / or the autoinjector 2, information regarding the completion of an injection, and / or information regarding an error condition of the autoinjector 2 to the user's device or the cloud. Signals indicative of needle insertion and / or premature device removal may also be transmitted via the wireless communication module. The controller 1408 may also be configured to transmit temperature information of the autoinjector 2. For example, the user may be able to monitor, via a mobile device and / or an application, the temperature of the autoinjector 2, for example, when the autoinjector 2 is removed from a refrigerator. The controller 1408 may also receive activation and / or delay commands via the wireless communication module. The controller 1408 may further receive operation adjustment commands, such as, for example, commands relating to adjustment of a preferred speed of operation. In some embodiments, the controller 1408 may receive a command to pause an injection.

[0101] In some embodiments, the controller 1408 may communicate with a mobile application on the user's mobile device via the wireless communication module. The mobile application may be configured to facilitate use of the autoinjector 2 and improve the user experience. In some embodiments, the mobile application may be used to automatically check the expiration date of the medication contained within the autoinjector 2. Such a feature may relieve the user from having to manually check the expiration date and may improve user safety. Based on the expiration date, the mobile device may be configured to warn the user and / or disable use of the autoinjector 2. In some embodiments, the mobile application may be used to warn the user about a product recall and / or disable the device in the event of a product recall. For example, the mobile application may access a database via the internet to determine whether a particular device, lot of device, medication, and / or lot of medication has been recalled. In some embodiments, the mobile application may be configured to verify whether the autoinjector 2 and / or medication is genuine and not counterfeit. The mobile application may perform the verification, for example, by matching the product serial number or digital signature against a database of authenticated products. In some embodiments, one or more parts of the autoinjector 2 may be disposable and the mobile application may be configured to verify the authenticity of such part or parts prior to use.

[0102] In some embodiments, a mobile application may be used to enable the injection sequence. For example, the mobile application may synchronize with the events of the injection sequence and provide contemporaneous instructions to the user as to when to perform which tasks (e.g., depress switch 1409, hold autoinjector 2 against the skin, remove autoinjector). In some embodiments, the instructions may be narrated audio. In some embodiments, the instructions may be provided visually via a display on the mobile device. In some embodiments, the mobile application may be configured to provide a detailed indication of the progress of the injection sequence. For example, the mobile application may provide textual, visual, and / or audible indications of the progress, e.g., at a finer granularity than that indicated by LEDs, as previously described herein.

[0103] In some embodiments, the mobile application may be configured to record and store the date and / or time of the injection. Based on the date and / or time of the injection and the user's prescription information, the mobile application may be configured to automatically create reminders for subsequent injections. In some embodiments, upon completion of the injection, the mobile application may be configured to provide a notification to the user with positive feedback for adherence to the prescription regimen. In some embodiments, the mobile application may provide points and / or rewards for continued adherence.

[0104] In some embodiments, the mobile application may be configured to authenticate a user of the autoinjector 2 prior to use. For example, the mobile application may use biometric authentication, two-factor authentication, or other suitable authentication protocols in conjunction with the user's mobile device to verify the user's identity prior to injection. In response to user authentication, the mobile application may activate or otherwise unlock the autoinjector. Such user authentication may curb misuse and / or waste of expensive medications by persons other than the intended user.

[0105] In some embodiments, the mobile application may be configured to detect the operational status of the autoinjector 2. For example, the mobile application may be configured to detect the battery level of the device, and in the event of a low battery indication, the mobile application may be configured to provide a notification to the user indicating the need to charge the device. In some embodiments, the mobile application may be configured to detect mechanical and / or electrical failures of the autoinjector 2 and communicate such information to the user.

[0106] FIG. 18 illustrates an exemplary method 2000 according to the present disclosure. The method 2000 begins at step 2002, where a user may place the autoinjector 2 on their body such that the tissue engaging surface 4 contacts a skin surface. The user may position the autoinjector 2 on their skin after removing the locking component 1610, as previously described herein, thereby allowing the touch sensor 1410 to detect the proximity of the skin. The autoinjector 2 may be attached to any suitable location, such as, for example, the thigh, abdomen, shoulder, forearm, upper arm, leg, buttocks, or another suitable location. The autoinjector 2 may be secured to the skin by an adhesive patch 12. Securing the autoinjector 2 at step 2002 may depress an activation switch 1409 extending outwardly from the tissue engaging surface 4 to interrupt a circuit. The interruption of the circuit may cause the controller 1408 to send a signal indicating that the activation switch 1409 has been pressed. Alternatively, any other suitable mechanism may power on or otherwise activate the auto-injector 2 before or after step 2002. When the activation switch 1409 is pressed, the auto-injector 2 may emit an audible sound and / or illuminate one or more LEDs (e.g., one or more LEDs of a first color, e.g., blue) to indicate the pressing of the activation switch 1409.

[0107] Once the autoinjector 2 is activated in step 2002, the method 2000 may proceed to step 2004 where the controller 1408 may determine whether the tissue engaging surface 4 is placed on a skin surface. In step 2004, the controller 1408 may receive a measurement from the touch sensor 1410 indicating whether the autoinjector 2 is placed on the skin or another surface. For example, if the controller 1408 determines that the touch sensor 1410 is in contact with the skin when the capacitance value received from the touch sensor 1410 is within a predetermined range, the method 2000 may proceed to step 2008. For example, if the controller 1408 determines that the touch sensor is not in contact with the skin when the capacitance measurement received from the touch sensor 1410 indicates that the autoinjector 2 is in contact with a non-skin surface such as wood or metal, the method 2000 may proceed to step 2006. In step 2006, the autoinjector 2 may be placed in an error state. In an error condition, an LED (e.g., a red LED) may be activated to indicate to the user that an error has occurred or a message may be displayed on a display screen. In some examples, the autoinjector 2 may need to be manually reset before the injection can be completed. In other examples, the autoinjector 2 may loop back to step 2004, where the controller 1408 continually attempts to determine if the touch sensor 1410 is in contact with the skin. The method 2000 may also require that the touch sensor 1410 be in contact with the skin during the entire injection. Thus, if at any point during the injection the controller 1408 determines that the touch sensor 1410 is no longer in contact with the skin, the controller 1408 may stop the injection (e.g., by stopping further movement of the translation mechanism 1366), generate an error signal or message, and cause the needle 306 to be retracted if it was extended. By stopping the injection and retracting the needle 306, the medication may be administered externally (ie, a wet injection) and / or the risk of needle stick injury may be reduced.Upon determination of step 2004, the autoinjector 2 may emit an audible sound and / or illuminate one or more LEDs to indicate that the autoinjector 2 has been placed on the skin surface. In one example, one or more additional LEDs of a first color may be illuminated at this stage to indicate further progress of the injection.

[0108] In step 2008, the controller 1408 may send a signal to actuate the translation mechanism 1366. When actuated, the translation mechanism 1366 may move toward the second end 1306 of the cartridge 1302 (see Figs. 13 and 14) and may move the cartridge 1302 itself in the same direction. This may move the needle 308 in the opposite direction to access the cartridge 1302, as described above. The movement of the driver 1398 and the needle 308 moves the carrier 202 in the same direction, which describes the sequence of events that ultimately deploys the needle 306 into the user, by the mechanism described in Figs. 5-11. The translation mechanism 1366 continues to move toward the second end 1306 until the desired amount of medication contained within the cartridge 1302 has been administered to the user. Upon actuation of the translation mechanism, the autoinjector 2 may emit an audible sound and / or illuminate one or more LEDs to indicate that an injection is in progress. For example, further additional LEDs of a first colour may be illuminated as the injection progresses to give the user a visual indication of progress.

[0109] Method 2000 proceeds to step 2010, where controller 1408 may determine whether the injection is complete. This determination may be based on the interruption of beam 1430 by piston 1316 (as described with reference to FIGS. 4A, 13, and 14). That is, when beam 1430 is interrupted (not received by detector 1416), controller 1408 may determine that the injection is complete. Once controller 1408 determines that the injection is complete, controller 1408 may send a signal to translation mechanism 1366 to reverse the direction of rotation of lead screw, which may cause lamp 1500 to push lamp 243 of stop 240 to allow retraction of needle 306, as described above with reference to FIG. 11. In one example, controller 1408 may provide a delay after receiving an indication that beam 1430 is interrupted. The delay may be, for example, 0.1 seconds to 60 seconds.

[0110] It should be noted that alternative end detection mechanisms may be used in place of or in conjunction with the interruption type sensor as described above. For example, the current of the motor of the translation mechanism 1366 may be utilized to determine whether the injection is complete. That is, when the piston 1316 reaches the second end 1306 of the cartridge 1302, the motor current increases (e.g., as a result of the piston 1316 engaging the end of the cartridge 1302) and ejection of all or substantially all of the contents of the cartridge 1302 is signaled. One exemplary combination may include the use of a beam 1430, where interruption of the beam 1430 indicates, for example, that 90-98 percent of the injection is complete. The current of the motor of the translation mechanism 1366 may then be analyzed to determine whether the remaining 2-10 percent of the injection is complete. In another example, instead of using an optical switch, a delay from the start of the translation mechanism 1366 may be used by the controller 1408 to determine when to reverse the translation mechanism 1366. In one example, the delay may be, for example, from about 1 second to about 120 seconds, although other suitable times are contemplated. In any event, the delay from the start may be long enough to allow the cartridge 1302 to be emptied. In yet another example, the beam 1430 may be used in conjunction with an encoder. The encoder may be configured to detect the position of the piston 1316. If the encoder alone were used to detect the position of the piston 1316, drive train issues may prevent accurate detection. For example, the piston 1316 may rotate when pushed by the lead screw. Such rotation may cause uncertainty as to the actual position of the piston 1316. However, when used in conjunction with the beam 1430, the controller 1408 may be configured to recalibrate the encoder in response to an interruption of the beam 1430. Such recalibration may enable the controller 1408 to update the actual position of the encoder and resume accurate detection of the position of the piston 1316 using the encoder.

[0111] Once the injection is determined to be complete, the autoinjector 2 may emit an audible sound and / or illuminate one or more LEDs to indicate completion of the injection. In some examples, one or more LEDs may be illuminated in a second color (e.g., green) different from the first color to inform the user that the injection is complete. In some examples, all LEDs on the device may be illuminated in the second color, and other indications may also be used. For example, all LEDs may be illuminated in the second color and may flash intermittently at the end of the injection.

[0112] In some examples, the timing of the injection procedure, measured from the initial activation of the activation switch 1409 to the retraction of the needle 306 away from the user after drug delivery, can be about 20 seconds to about 90 seconds, or about 25 seconds to about 60 seconds, about 30 seconds to about 45 seconds, or about 120 seconds or less, or about 90 seconds or less, or about 60 seconds or less, or about 45 seconds or less, or about 30 seconds or less. Such timings represent a significant improvement over existing devices, where the timing of the injection can be significantly longer, in some cases up to about 9 minutes or more.

[0113] The method 2000 may also include additional steps. For example, the method 2000 may include steps of determining whether the medication in the cartridge 1302 is too cold for delivery to the user, whether the power source 1406 has sufficient energy to complete the injection, whether the needle 306 was prematurely deployed and / or retracted, whether the current of the motor of the translation mechanism 1366 is within an appropriate range, and whether the injection procedure has extended beyond a maximum allowable procedure time. Upon detecting any of the above errors, the controller 1408 may communicate such error to the user and terminate the ongoing injection, for example, by stopping or reversing the translation mechanism 1366 and retracting the needle 306 away from the user. The autoinjector 2 may emit an audible sound and / or illuminate one or more LEDs indicative of any of the aforementioned additional steps. For example, one or more LEDs of a third color (e.g., red) different from the first and second colors may be illuminated.

[0114] 20 illustrates an example method 2020 for controlling the torque of a motor of the translation mechanism 1366 and detecting when the motor has stalled. At step 2022, the controller 1408 may initiate an injection sequence. As previously described herein, the injection sequence may be initiated in response to pressing the activation switch 1409 against the user's skin and / or detecting the user's skin by the touch sensor 1410. During the injection sequence, a voltage may be applied to the motor of the translation mechanism 1366 to drive the motor.

[0115] In step 2024, as the injection sequence progresses, the controller 1408 may maintain the motor of the translation mechanism 1366 at a constant speed. The constant speed may be, for example, a rotational speed measured in revolutions per minute (RPM). The controller 1408 may maintain the motor at a constant speed by varying the voltage applied to the motor. For example, if a higher load is applied to the motor due to an obstruction, increased fluid pressure, increased part friction, or other cause, the controller 1408 may compensate for the increased load by increasing the voltage applied to the motor. Conversely, if the load applied to the motor decreases, the controller 1408 may compensate for the decreased load by decreasing the voltage applied to the motor. Maintaining the motor at a constant speed may reduce the likelihood that the user will experience pain at the injection site. For example, maintaining the motor at a constant speed may prevent the bolus from becoming too large, thereby reducing the risk of pain.

[0116] During the injection sequence, the controller 1408 may monitor the current provided to the motor. The motor current may be indicative of the torque generated by the motor. For example, a higher motor current may be indicative of a higher torque being generated by the motor. In step 2026, the controller 1408 may determine whether the motor current exceeds a first current threshold. The first current threshold may be determined and / or set based on a maximum torque that can be safely generated by the motor. The maximum torque may be reached, for example, when the injection sequence is interrupted in some way. If the controller 1408 determines that the motor current does not exceed the first current threshold, the method 2020 may return to step 2024, where the controller 1408 may continue to maintain the motor at a constant speed. On the other hand, if the controller 1408 determines that the motor current does exceed the first current threshold, the method 2020 may proceed to step 2028.

[0117] In step 2028, the controller 1408 may decrease the motor voltage to maintain the motor current below the second current threshold. In some embodiments, the second current threshold may be a value greater than the first current threshold and may more closely correlate to the maximum torque the motor can safely generate. In some embodiments, the second current threshold may be less than or equal to the first current threshold. If the injection sequence is interrupted, the motor speed may slow and the motor impedance may decrease. As the motor impedance decreases, less voltage may be required to maintain the motor current below the second current threshold. The controller 1408 may monitor the average motor voltage applied to the motor. The average motor voltage may be, for example, a time average.

[0118] Steps 2024-2028 of method 2020 may be generally illustrated by the graph depicted in Figure 20B, which plots a curve representing the relationship between the voltage applied to the motor of translation mechanism 1366 and the current consumed by the motor. The curve may be characterized by the following equation:

[0119] V=iR+V emf Here, V is the voltage applied to the motor, i is the motor's current consumption, R is the motor's coil resistance, and V emf is the back electromotive force acting against the applied voltage at a given speed. As shown in FIG. 20B, the curve may include a constant speed region where the motor may be maintained at a constant speed (step 2024). In the constant speed region, V emf may remain approximately constant and the curve may be approximately linear.

[0120] 20B, as the load (i.e., torque) acting on the motor of the translation mechanism 1366 increases, the current consumed by the motor may increase. As the current approaches the maximum current, the voltage applied to the motor may be decreased (steps 2026 and 2028) to thereby maintain the current below the maximum current. The current consumed by the motor may be maintained below the maximum current using proportional-integral (PI) control. As shown, there may be a minimum voltage at the motor at which the motor may stall.

[0121] Steps 2030-2038 of method 2020 may correspond to a control sequence for preventing the motor from stalling. Figure 20A shows a graph that may represent the voltage applied to and current consumed by the motor over time according to steps 2030-2038.

[0122] In step 2030, the controller 1408 may determine whether the average motor voltage has fallen below a first threshold voltage. A fall of the average motor voltage below the first threshold voltage may indicate that the injection sequence is being interrupted. If the controller 1408 determines that the average motor voltage has not fallen below the first threshold voltage, the method 2020 may return to step 2028, and the controller 1408 may continue to maintain the motor current below the second current threshold. FIG. 20A illustrates five intervals during which the controller 1408 may maintain the motor current at a constant value (e.g., below the second current threshold): from about 35 seconds to about 37 seconds, from about 39 seconds to about 41.5 seconds, from about 43.5 seconds to about 46 seconds, from about 48 seconds to about 50.5 seconds, and from about 52.5 seconds to about 55 seconds. As shown in Figure 20A, the voltage applied to the motor during each interval may decrease, with some variation, to maintain the motor current below the second current threshold. Although the voltage during each interval in Figure 20A is shown decreasing, the voltage does not necessarily have to decrease to maintain the motor current below the second current threshold, but instead may remain flat in certain circumstances.

[0123] On the other hand, if the controller 1408 determines that the average motor voltage has fallen below the first threshold voltage, the controller 1408 may pause the injection sequence for a first time interval. When pausing the injection sequence, the controller 1408 may stop applying voltage to the motor. In some embodiments, the first time interval may be, for example, 2 seconds. FIG. 20A shows four such pauses, between about 37 seconds and about 39 seconds, between about 41.5 seconds and about 43.5 seconds, between about 46 seconds and about 48 seconds, and between about 50.5 seconds and about 52.5 seconds.

[0124] The first time interval may be long enough to allow fluid pressure within the autoinjector 2 to dissipate. The first time interval may also be short enough so that the user is not prompted to remove the autoinjector 2 from the user's skin (e.g., the first time interval is set to be shorter than a user's typical reaction time to erroneously identify the end of an injection). The first time interval may also be indicated by the illumination of one or more of the LEDs of the progress ring or another light within the autoinjector 2 and be visible to the user. The LEDs may be illuminated, for example, in a particular pattern or according to a particular color scheme to indicate the first time interval and that the injection sequence has been paused rather than stopped.

[0125] After pausing the injection sequence, the controller 1408 may continue the injection sequence at step 2034. To continue the injection sequence, the controller 1408 may resume supplying voltage to the motor of the translation mechanism 1366. In step 2036, the controller 1408 may determine whether the average motor voltage has fallen below the first threshold voltage within a second time interval. The second time interval may be of a shorter length than the first time interval and may be set and / or determined to indicate a confirmation that the injection sequence is being disturbed. The second time interval may be, for example, about 0.9 seconds. If the motor voltage has not fallen below the first threshold voltage within the second time interval, the method 2020 may return to step 2030. On the other hand, if the controller 1408 determines that the motor voltage has fallen below the first threshold voltage within the second time interval, the method 2020 may proceed to step 2038, where the controller 1408 may abort the injection sequence.

[0126] In some embodiments, the controller 1408 may perform step 2026 continuously when performing steps 2028-2036. For example, the controller 1408 may continue to determine whether the motor current exceeds the first current threshold when steps 2028-2036 are performed. If the motor current continues to exceed the first current threshold, the method 2020 may proceed to steps 2028-2036 as previously described herein. On the other hand, if the motor current falls below the first current threshold, the method 2020 may return to step 2024 and the controller 1408 may maintain the motor at a constant speed. In other words, if a high load on the motor due to an obstacle, high fluid pressure, etc., dissipates during the performance of steps 2028-2036, the controller 1408 may simply revert to maintaining a constant motor speed rather than proceeding unnecessarily with the remaining steps.

[0127] Thus, the method 2020 may enable the controller 1408 to effectively distinguish between a situation where the needle may be partially blocked or high frictional forces may act against the injection sequence and a situation where the injection sequence is insurmountably impeded. In the former situation, the autoinjector 2 has the ability to complete the injection sequence and the injection sequence is not terminated prematurely. In the latter situation, the autoinjector 2 does not have the ability to complete the injection sequence and the injection sequence is properly terminated. In such a situation, the autoinjector 2 may emit an audible sound and / or illuminate one or more LEDs to indicate that the injection has been terminated before completion. The method 2020 may further properly terminate the injection sequence with the piston 1316 fully extended to indicate that the cartridge 1302 is empty. The method 2020 may further enable the autoinjector 2 to be used on an emergency basis, for example, when a user performs an injection without first warming the autoinjector 2 to reduce the viscosity of the medicament. The method 2020 may further allow the injection of a viscous medication to proceed at a slower speed than the motor and gear reduction ratio might otherwise allow.

[0128] 21 illustrates an example method 2100 for detecting the end of administration of a medication using an emitter 1414 and a detector 1416. The method 2100 may be used, for example, to detect the time when a full dose of a medication has been administered to a user and to terminate the corresponding injection sequence.

[0129] In step 2102, the controller 1408 may initiate an injection sequence. As previously described herein, the injection sequence may be initiated in response to pressing the activation switch 1409 against the user's skin and / or detecting the user's skin by the touch sensor 1410. In step 2104, the controller 1408 may cycle the emitter 1414 on and off periodically. The emitter 1414 may be cycled on and off rapidly in a square wave pattern such that the emitter 1414 is turned off and on several times per second. Cycling the emitter 1414 on and off may allow the detector 1416 to be exposed to light generated by the emitter 1414 in combination with ambient light, and also to ambient light alone.

[0130] In step 2106, the controller 1408 may receive a first signal from the detector 1416 corresponding to a time when the emitter 1414 is off. The first signal may correspond to and / or be indicative of ambient light detected by the detector 1416. In step 2108, the controller 1408 may receive a second signal from the detector 1416 corresponding to a time when the emitter 1414 is on. The second signal may correspond to and / or be indicative of light emitted by the emitter 1414 combined with ambient light as detected by the detector 1416.

[0131] In step 2110, the controller 1408 may calculate a difference between the first light value represented by the first signal and the second light value represented by the second signal. This difference may indicate the amount of light detected by the detector 1416 that is due to light emitted by the emitter 1414 rather than ambient light. In step 2112, the controller 1408 may determine whether the difference is less than a threshold. If the controller 1408 determines that the difference is not less than the threshold, the method 2100 may return to step 2106. On the other hand, if the controller 1408 determines that the difference is less than the threshold, the controller 1408 may end the injection sequence in step 2114.

[0132] Thus, method 2100 can be used to reduce the effects of ambient light when detecting the end of administration of a medication. Specifically, method 2100 can address a situation where light from emitter 1414 indicating the end of administration is blocked from reaching detector 1416, yet ambient light is able to reach detector 1416, creating a false negative reading indicating that the end of administration has not been reached.

[0133] 22 illustrates another exemplary method 2200 of detecting the end of administration of a medication using an emitter 1414 and a detector 1416. The method 2200 may be used, for example, to detect the time when a full dose of a medication has been administered to a user and to terminate the corresponding injection sequence.

[0134] In step 2202, the controller 1408 may initiate an injection sequence. As previously described herein, the injection sequence may be initiated in response to depressing an activation switch 1409 against the user's skin and / or detecting the user's skin by a touch sensor 1410. In step 2204, the controller 1408 may activate or otherwise cause the emitter 1414 to emit light.

[0135] In step 2206, the controller 1408 may allow the injection sequence to continue for a first period of time. The first period of time may be a predetermined period of time corresponding to a period during which the full dose is unlikely or unlikely to be administered. For example, the first period of time may be approximately 20%-50% of the total injection time. During the first period of time, the controller 1408 cannot interrupt the injection sequence in response to a signal received from the detector 1416 (although the injection sequence may be interrupted due to an obstruction or stall, as described with reference to FIG. 20).

[0136] In step 2208, after the end of the first period, the controller 1408 may determine whether the amount of light received by the detector 1416 is less than a first threshold amount of light. The controller 1408 may make the determination based on a signal received from the detector 1416 indicative of the light received by the detector 1416. The first threshold amount of light may correspond to the amount of light received by the detector 1416 at the end of administration. If the controller 1408 determines that the amount of light received by the detector 1416 is not less than the first threshold amount of light, the controller 1408 may continue with the injection sequence and the method 2200 may remain at step 2208. On the other hand, if the controller 1408 determines that the amount of light received by the detector 1416 is less than the first threshold amount of light, the method may proceed to step 2210.

[0137] In step 2210, the controller 1408 may determine whether the amount of light received by the detector 1416 is equal to or greater than the first threshold amount of light. If the controller 1408 determines that the amount of light received by the detector 1416 rises to or greater than the first threshold amount of light, the controller 1408 may continue the injection sequence and the method 2200 may return to step 2208. On the other hand, if the controller 1408 determines that the amount of light received by the detector 1416 remains below the first threshold amount of light, the method may proceed to step 2212. Step 2210 may, in effect, allow the controller 1408 to "clear" an abnormal interruption in the injection sequence of light received by the detector, which may be caused, for example, by an air bubble in the cartridge 1302 blocking the path of light between the emitter 1414 and the detector 1416 if the amount of light subsequently meets or exceeds the first threshold amount of light.

[0138] In step 2212, the controller 1408 may determine whether the motor current exceeds a first current threshold. The first current threshold may be determined and / or set based on a current indicating the end of the injection sequence. The first current threshold may be set, for example, based on a current indicating that the piston 1316 has reached the second end 1306 of the cartridge 1302. If the controller 1408 determines that the motor current does not exceed the first current threshold, the controller 1408 may continue the injection sequence and the method 2200 may return to step 2208. On the other hand, if the controller 1408 determines that the motor current has exceeded the first current threshold, the method 2200 may proceed to step 2214, where the controller 1408 may terminate the injection sequence.

[0139] Thus, method 2200 may enable accurate identification of the end of an injection sequence by identifying the moment when both the light received by detector 1416 and the motor current indicate the end of administration. By sequentially performing steps 2208, 2210, and 2212, erroneous identification of the end of administration due to only either an anomalous interruption of the light or an anomalous high current event may be mitigated. Method 2200 may, in particular, reduce the effect of air bubbles in cartridge 1302 on the detection of the end of administration of medication.

[0140] Figure 23 illustrates an exemplary method 2300 of operating an activation switch 1409 of an autoinjector 2 in accordance with the present disclosure. In particular, Figure 23 illustrates an exemplary sequence of positions of the activation switch 1409 and the corresponding functions of the autoinjector 2.

[0141] Initially, in step 2302, the autoinjector 2 may be placed in a package such that the plunger 1450 is in a depressed state and the autoinjector 2 is in a low power sleep mode. In some embodiments, during manufacturing, the autoinjector 2 may be programmed to an awake or active state. In some embodiments, the autoinjector 2 may be configured to transition to a low power sleep mode if the plunger 1450 is depressed for a predetermined period of time after programming, such as when the autoinjector is placed in the package. The predetermined period of time may be any suitable period of time, such as 60 minutes, 30 minutes, 15 minutes, 10 minutes, 5 minutes, 2 minutes, or any other suitable period of time. The autoinjector 2 may be sealed in the package such that the package indicates that the autoinjector 2 has not been used previously. The package may be made of any suitable material, including paper, cardboard, plastic, cellophane, and the like. The packaging may press the plunger 1450 so that it is flush or nearly flush with the housing 3 of the autoinjector 2, preventing the plunger 1450 from extending outwardly from the autoinjector 2. With the plunger 1450 depressed, the circuit associated with the activation switch 1409 is open, thereby keeping the autoinjector 2 in a low power sleep mode.

[0142] In step 2304, the autoinjector 2 may be removed from the packaging such that the plunger 1450 is no longer depressed by the packaging and extends outwardly from the autoinjector 2. As the plunger 1450 transitions from the depressed state to the free or extended state, the plunger flange 1454 may contact or otherwise depress the plunger switch 1448, thereby completing a circuit associated with the activation switch 1409.

[0143] In step 2306, in response to the circuitry associated with the activation switch 1409 being complete, the autoinjector may transition from a low power sleep mode to an active mode. In the active mode, the autoinjector 2 may calibrate the touch sensor 1410. The autoinjector 2 may calibrate the touch sensor 1410 by detecting a value or measurement of the touch sensor 1410 in ambient air that is not in contact with the user's skin. The autoinjector 2 may perform such calibration during a predetermined period of time after the autoinjector 2 is removed from the package (or, in some cases, immediately after removal), and before the user exposes their skin to the touch sensor 1410. In the active mode, the autoinjector 2 may further detect whether the emitter 1414 and / or detector 1416 are functioning properly, detect whether the needle is properly positioned, detect whether the motor of the translation mechanism 1366 is responsive and / or operable, and / or perform other appropriate condition tests. The autoinjector 2 may detect needle placement, for example, using a switch or detector configured to report the needle position to the controller 1408. In the active mode, the autoinjector 2 may further illuminate one or more backlights to allow a user to inspect the vial and / or medication contained therein through the transparent window 50. In the active mode, the autoinjector 2 may further display other indications that the autoinjector 2 is ready to be used.

[0144] At step 2308, the autoinjector 2 may be placed against the skin of the user such that the plunger 1450 is depressed into the autoinjector 2. When the plunger 1450 is depressed, the activation switch 1409 and associated circuitry may transition to an open state. As described above with reference to FIG. 18 and method 2000, the autoinjector 2 may further detect contact with the skin using the touch sensor 1410. In response to depression of the plunger 1450 and detection of contact with the skin, the autoinjector 2 may initiate an injection sequence at step 2310. The injection sequence may be a sequence that results in an injection of a medication into the user, as previously described herein.

[0145] In step 2312, the autoinjector 2 is removed from the user's skin and the plunger 1450 may again extend outward from the autoinjector 2. Once the plunger 1450 extends outward, the activation switch 1409 and associated circuitry may transition from an open state to a closed state. In response, the autoinjector 2 may terminate the injection sequence in step 2310 and initiate retraction of the patient's needle, for example by reversing the motor. The autoinjector 2 may initiate needle retraction to prevent a wet injection if the injection sequence has progressed to completion or if the autoinjector is prematurely or accidentally removed from the skin. Alternatively, in some embodiments, the controller 1408 may determine whether the value received from the touch sensor 1410 indicates that the autoinjector 2 remains in contact with the user's skin. If the value received by the controller 1408 indicates that the autoinjector 2 remains in contact with the user's skin, the autoinjector 2 may pause the injection sequence, thereby preventing a wet injection. When the plunger 1450 is depressed again, thereby opening the circuit associated with the activation switch 1409, the autoinjector 2 may resume the injection sequence.

[0146] In accordance with the method 2300 described above, the activation switch 1409 may function to keep the autoinjector 2 in a low power sleep mode while in the package, transition the autoinjector 2 into an active mode when removed from the package, indicate when the autoinjector 2 has been placed against the user's skin for an injection sequence, and indicate when the autoinjector 2 has been removed from the user's skin at the end of the injection sequence. Additionally, the signal from the activation switch 1409 may be matched against a signal from the touch sensor 1410 to more accurately determine whether the autoinjector 2 has been removed from the user's skin or whether, for example, an inadvertent or minor movement of the autoinjector has occurred.

[0147] It should be understood that one or more steps of the various methods described herein may be combined in certain embodiments. Furthermore, in some embodiments, less than all of the method steps described herein may be performed and / or additional steps not described herein may be performed. Furthermore, the steps described herein do not necessarily have to be performed in the exact order presented.

[0148] In particular, reference to "one embodiment" or "embodiment" herein means that a particular feature, structure, or characteristic described in connection with an embodiment may be included in, employed, and / or incorporated in one, some, or all of the embodiments of the present disclosure. The use or appearance of the phrase "in one embodiment" or "in another embodiment" herein does not refer to the same embodiment, nor does the separate or alternative embodiment necessarily mutually exclude one or more other embodiments, nor is it limited to a single exclusive embodiment. The same applies to the terms "implementation" and "example". The present disclosure is not limited to any single aspect or embodiment thereof, nor to any combination and / or permutation of such aspects and / or embodiments. Furthermore, each of the aspects and / or embodiments of the present disclosure may be used alone or in combination with one or more of the other aspects and / or embodiments of the present disclosure. For the sake of brevity, certain permutations and combinations are not separately described and / or illustrated herein.

[0149] Furthermore, as noted above, any embodiment or implementation described herein as "exemplary" should not be construed as being preferred or advantageous over other embodiments or implementations, for example, but rather is intended to convey or illustrate that one or more embodiments are exemplary embodiment(s).

[0150] The present disclosure is further illustrated by the following non-limiting sections. Item 1. An injection device, comprising: Housing and a vessel disposed within the housing, the vessel containing a fluid and having a first end and a second end; a conduit movable relative to the container, the conduit being configured to be out of fluid communication with the fluid contained by the container when in a first position and in fluid communication with the fluid contained by the container when in a second position to deliver the fluid from the container to a patient; a lock removable from the housing, the lock having a first portion and a second portion; in a first configuration in which the lock is coupled to the housing, the first portion of the lock is disposed external to the housing and the second portion of the lock is disposed within the housing between the container and the conduit; in the first configuration, the conduit is prevented from moving into fluid communication with the fluid contained by the container by the second portion of the lock; 2. The injection device of claim 1, further comprising: in a second configuration in which the lock is removed from the injection device, the conduit is movable into fluid communication with the fluid contained by the container.

[0151] Item 2. An adhesive disposed on the exterior of the housing; a cover disposed over the adhesive, the cover being removable from the injection device to expose the adhesive; 2. The injection device according to item 1, wherein the lock is coupled to the cover such that the lock is removed from the injection device when the cover is removed from the injection device.

[0152] Item 3. Further comprising a controller and a skin sensor coupled to the controller, the skin sensor is configured to detect skin contact with an exterior surface of the housing adjacent the skin sensor; the controller is configured to move the conduit into fluid communication with the fluid contained by the vessel; 2. The injection device of claim 1, wherein when the lock is coupled to the housing in the first configuration, the first portion of the lock is configured to prevent skin from contacting the exterior surface of the housing adjacent the skin sensor.

[0153] Item 4. The injection device of item 1, wherein when in the first configuration, the lock is configured to prevent inadvertent actuation of the injection device when the injection device is dropped or subjected to vibration.

[0154] Item 5. An injection device, Housing and a plunger coupled to the housing and movable relative to the housing; one or more electronic components used during an injection performed by said injection device, said electronic components being formed in an electrical circuit, in a first configuration, a first portion of the plunger is disposed within the housing, the electrical circuit is open, and the one or more electronic components are in a low power sleep mode; In a second configuration, the plunger moves outwardly relative to the housing and the first portion of the plunger extends outside the housing; In the second configuration, the electrical circuit is closed and the one or more electronic components are transitioned from the low power sleep mode to an active mode.

[0155] Item 6. Further comprising a biasing member movable from a rest position to a pressure position, In the first configuration, the biasing member is in the pressure position, 6. The injection device according to claim 5, wherein in the second configuration, the biasing member is in the rest position.

[0156] Item 7. The injection device of item 6, further comprising a stop configured to maintain the biasing member in the pressurized position and maintain the plunger in the first configuration when the stop is in a blocking position, and movement of the stop from the blocking position causes the biasing member to move to the rest position and allows the plunger to move to the second configuration.

[0157] Item 8. The injection device according to item 7, wherein the stopper comprises a package for the injection device. Item 9. The injection device of item 5, wherein the one or more electronic components include a switch, and transition of the plunger from the first configuration to the second configuration moves the switch to close an electrical circuit.

[0158] Item 10. The plunger is movable from the second configuration to a third configuration toward the housing; 6. The injection device according to item 5, wherein the injection device is configured to initiate an injection by the injection device only after the plunger has been moved to the third configuration and the one or more electronic components are in the active mode.

[0159] Item 11. The one or more electronic components include a skin sensor, and the injection device further includes a controller configured to initiate an injection by the injection device; the skin sensor is configured to detect the presence of skin in contact with an exterior surface of the housing adjacent the skin sensor only after the plunger has moved to the third configuration; 11. The injection device according to claim 10, wherein the controller is configured to initiate an injection only after detection of the skin by the skin sensor. Item 12. The injection device further comprises a motor configured to dispense a medicament from the injection device during injection. During the injection, the plunger is movable from the third configuration to a fourth configuration spaced from the housing; Item 12. The injection device of item 11, wherein the controller is configured to stop operation of the motor while the motor is operating and the controller detects that the plunger has moved from the third configuration to the fourth configuration.

[0160] Item 13. The controller, determining that the plunger is in the fourth configuration while skin remains in contact with the exterior surface of the housing adjacent the skin sensor; Item 13. The injection device of item 12, wherein the controller resumes operation of the motor when the plunger moves from the fourth configuration to the third configuration after the controller determines that the plunger was in the fourth configuration but that skin remained in contact with the exterior surface of the housing adjacent the skin sensor.

[0161] Item 14. An injection device a housing including a curved underside, the curved underside being concave when viewed from a point on the exterior of the housing that is closer to the underside of the housing than to an upper surface of the housing; a circuit board disposed adjacent the lower surface of the housing, the circuit board including a skin sensor configured to detect the presence of skin in contact with the lower surface of the housing; a controller coupled to the circuit board, the controller configured to initiate an injection by the injection device only after the skin sensor detects the presence of skin in contact with the underside of the housing.

[0162] Item 15. The injection device of item 14, wherein the skin sensor is configured to detect the presence of skin in contact with the underside of the housing without the skin directly contacting the skin sensor.

[0163] Item 16. The injection device of item 14, wherein the skin sensor is a capacitance sensor. Item 17. The housing further includes an opening in the curved lower surface, The injection device further comprises a needle extendable through the opening and out of the housing; Item 15. The injection device according to item 14, wherein the skin sensor is positioned adjacent to the opening.

[0164] Item 18. The injection device according to item 14, wherein the circuit board is the only circuit board disposed within the housing. Item 19. A method for producing an injection device, comprising: depositing a first material having a first opacity onto a mold; depositing a second material around the mold and the first material, the second material having a second opacity that is higher than the first opacity; and disposing a container containing a medicament within the injection device and adjacent to a first portion of the injection device formed from the first material.

[0165] Item 20. The method of item 19, further comprising the step of disposing one or more LEDs in the injection device adjacent to one or more second parts of the injection device separate from the first part of the injection device, wherein the one or more second parts of the injection device are formed by the first material.

[0166] Item 21. An injection device, a container disposed within the housing, the container having a first end and a second end; a piston configured to move from the first end of the container toward the second end of the container to dispense a medicament from the container; a drive member configured to drive the piston through the container; an emitter configured to emit a beam of light toward the container; a detector disposed on an opposite side of the vessel from the emitter, the detector configured to receive the light beam emitted from the emitter; a controller coupled to the drive member, the emitter, and the detector, the controller comprising: receiving a first signal from the detector while the emitter is off, the first signal corresponding to an ambient light level surrounding the injection device; receiving a second signal from the detector while the emitter is on; calculating a difference between the light values ​​represented by the first signal and the second signal; The injection device configured to stop movement of the drive member when the difference is below a threshold value.

[0167] Item 22. An injection device, a container disposed within the housing, the container having a first end and a second end; a piston configured to move from the first end of the container toward the second end of the container to dispense a medicament from the container; a drive member configured to drive the piston through the container; an emitter configured to emit a beam of light toward the container; a detector disposed on an opposite side of the vessel from the emitter, the detector configured to receive the light beam emitted from the emitter; a controller coupled to the drive member, the emitter, and the detector, the controller comprising: activating the drive member and the emitter; receiving a first signal from the detector representative of an amount of light received by the detector while the emitter is on; enabling continued operation of the drive member for a first period of time immediately following initiation of the drive member; an injection device configured to stop operation of the drive member when (1) the amount of light received by the detector is less than a first threshold amount of light, and (2) determine that the current in the drive member is greater than a first current threshold before the amount of light received by the detector subsequently rises to or above the first threshold amount of light.

[0168] Item 23. The controller, 23. The injection device according to claim 22, configured to continue operation of the drive member if the determined amount of light received by the detector is less than the first threshold and the amount of light received by the detector rises to or above the first threshold amount of light before the current in the drive member exceeds the first current threshold.

[0169] Item 24. An injection device, a container disposed within the housing, the container having a first end and a second end; a piston configured to move from the first end of the container toward the second end of the container to dispense a medicament from the container; a drive member configured to drive the piston through the container; a controller coupled to the drive member, the controller comprising: maintaining the velocity of the drive member until a current in the drive member exceeds a first threshold; an injection device configured to reduce a voltage of the drive member after the current in the drive member exceeds the first threshold to maintain the current in the drive member below a second threshold that is greater than or equal to the first threshold.

[0170] Item 25. Further comprising a controller and a skin sensor coupled to the controller, the skin sensor is configured to detect skin contact with an exterior surface of the housing adjacent the skin sensor; the controller is configured to move the conduit into fluid communication with the fluid contained by the vessel; Item 1, the injection device further comprising a removable cover configured to prevent skin from contacting the exterior surface of the housing adjacent the skin sensor.

[0171] Item 26. The method of claim 20, further comprising: disposing a conduit movable relative to the container within the injection device such that the conduit is not in fluid communication with the fluid contained by the container; the first portion includes a first transparent window through which the interior of the injection device can be viewed; 20. The method of claim 19, wherein the container is visible through the first transparent window.

[0172] Item 27. The first portion further includes a plurality of second transparent windows disposed on an upper surface of the injection device, and at least one LED is visible through each of the plurality of second transparent windows; Item 27. The method of item 26, wherein the first transparent window and the plurality of second transparent windows are collectively formed from a continuous portion of the first material.

Claims

1. 1. An injection device comprising: Housing and a container disposed within the housing, the container containing a fluid and having a first end and a second end; a conduit movable relative to the container, the conduit configured to be out of fluid communication with the fluid contained by the container when in a first position and to be in fluid communication with the fluid contained by the container when in a second position to deliver the fluid from the container to a patient; a lock removable from the housing, the lock having a first portion and a second portion; In a first configuration in which the lock is coupled to the housing, the first portion of the lock is located external to the housing and the second portion of the lock is located within the housing between the container and the conduit; In the first configuration, the conduit is prevented from moving into fluid communication with the fluid contained by the container by the second portion of the lock; In a second configuration in which the lock is removed from the injection device, the conduit is movable into fluid communication with the fluid contained by the container.

2. an adhesive disposed on the exterior of the housing; a cover disposed over the adhesive, the cover being removable from the injection device to expose the adhesive; 2. The injection device of claim 1, wherein the lock is coupled to the cover such that the lock is removed from the injection device when the cover is removed from the injection device.

3. a controller; and a skin sensor coupled to the controller; the skin sensor is configured to detect skin contact with an exterior surface of the housing adjacent the skin sensor; the controller is configured to move the conduit into fluid communication with the fluid contained by the vessel; 2. The injection device of claim 1, wherein the first portion of the lock is configured to prevent skin from contacting the exterior surface of the housing adjacent the skin sensor when the lock is coupled to the housing in the first configuration.

4. 2. The injection device of claim 1, wherein when in the first configuration, the lock is configured to prevent inadvertent actuation of the injection device when the injection device is dropped or subjected to vibration.

5. 1. An injection device comprising: Housing and a plunger coupled to the housing and movable relative to the housing; one or more electronic components used during an injection performed by said injection device, said one or more electronic components being formed in an electrical circuit; In a first configuration, a first portion of the plunger is disposed within the housing, the electrical circuit is open, and the one or more electronic components are in a low power sleep mode; In a second configuration, the plunger moves outward relative to the housing, and the first portion of the plunger extends outside the housing; In the second configuration, the electrical circuit is closed and the one or more electronic components are transitioned from the low power sleep mode to an active mode.

6. a biasing member movable from a rest position to a pressure position; In the first configuration, the biasing member is in the pressure position; 6. The injection device of claim 5, wherein in the second configuration, the biasing member is in the rest position.

7. 7. The injection device of claim 6, further comprising a stop configured to maintain the biasing member in the pressurized position and maintain the plunger in the first configuration when the stop is in a blocking position, and movement of the stop from the blocking position moves the biasing member to the rest position and allows the plunger to move to the second configuration.

8. 8. The injection device of claim 7, wherein the stopper comprises a package of the injection device.

9. 6. The injection device of claim 5, wherein the one or more electronic components include a switch, and transition of the plunger from the first configuration to the second configuration moves the switch to close the electrical circuit.

10. the plunger is movable from the second configuration to a third configuration toward the housing; 6. The injection device of claim 5, wherein the injection device is configured to initiate an injection only after the plunger has been moved to the third configuration and the one or more electronic components are in the active mode.

11. the one or more electronic components include a skin sensor, and the injection device further comprises a controller configured to initiate an injection by the injection device; the skin sensor is configured to detect the presence of skin in contact with an exterior surface of the housing adjacent the skin sensor only after the plunger has moved to the third configuration; 11. The injection device of claim 10, wherein the controller is configured to initiate injection only after detection of skin by the skin sensor.

12. further comprising a motor configured to dispense a medication from the injection device during an injection; During injection, the plunger is movable from the third configuration to a fourth configuration spaced from the housing; 12. The injection device of claim 11, wherein the controller is configured to stop operation of the motor while the motor is operating and the controller detects that the plunger has moved from the third configuration to the fourth configuration.

13. The controller determining that the plunger is in the fourth configuration but that skin remains in contact with the exterior surface of the housing adjacent the skin sensor; 13. The injection device of claim 12, wherein the controller resumes operation of the motor when the plunger moves from the fourth configuration to the third configuration after determining that the plunger was in the fourth configuration but skin remained in contact with the exterior surface of the housing adjacent the skin sensor.

14. 1. An injection device comprising: a housing including a curved lower surface, the curved lower surface being concave when viewed from a point on the exterior of the housing that is closer to the lower surface of the housing than to the upper surface of the housing; a circuit board disposed adjacent the lower surface of the housing, the circuit board including a skin sensor configured to detect the presence of skin in contact with the lower surface of the housing; a controller coupled to the circuit board, the controller configured to initiate an injection by the injection device only after the skin sensor detects the presence of skin in contact with the underside of the housing.

15. 15. The injection device of claim 14, wherein the skin sensor is configured to detect the presence of skin in contact with the lower surface of the housing without the skin directly contacting the skin sensor.

16. 15. The injection device of claim 14, wherein the skin sensor is a capacitance sensor.

17. the housing further includes an opening in the curved lower surface; the injection device further comprising a needle extendable through the opening to an exterior of the housing; 15. The injection device of claim 14, wherein the skin sensor is positioned adjacent to the opening.

18. 15. The injection device of claim 14, wherein the circuit board is the only circuit board located within the housing.

Images